



Ref.: C.L.9.2018

Всемирная организация здравоохранения свидетельствует свое уважение и, в соответствии со статьями 3.A и 7 «Процедуры отбора рекомендуемых международных непатентованных наименований фармацевтических препаратов», принятой ... Исполнительным комитетом в его резолюции EB15.R7¹, имеет честь препроводить перечень наименований, который был опубликован как Международные непатентованные наименования, рекомендованные Всемирной организацией здравоохранения (сокращенно: Рекомендуемые МНН).

В соответствии со статьей 8 вышеуказанной Процедуры, Всемирная организация здравоохранения просит признать прилагаемый перечень наименований* в качестве непатентованных наименований указанных препаратов и принять необходимые меры, чтобы предупредить приобретение прав собственности на эти наименования, в том числе запретить регистрацию этих наименований в качестве торговых марок или торговых названий.

ЖЕНЕВА, 27 марта 2018 г.

¹ Приложение к резолюции EB15.R7, *Официальные документы Всемирной организации здравоохранения*, No. 60, сс. 3 и 55 (англ. изд.). В этот же текст были внесены изменения на основании резолюции EB43.R9, *Официальные документы Всемирной организации здравоохранения*, No. 173, с. 10 (англ. изд.), и резолюции EB115.R4, *Исполнительный комитет, Сто пятнадцатая сессия, Резолюции и решения (EB115/2005/REC/1)*, с. 2.

... ПРИЛ.: (1)* *Рекомендуемые МНН: Перечень 79, опубликованный в журнале WHO Drug Information, том 32, No.1, 2018 год.*

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 79

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can be found in *Cumulative List No. 17, 2017* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 79

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la *Liste récapitulative No. 17, 2017* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 79

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en *Cumulative List No. 17, 2017* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

*Chemical name or description; Molecular formula;
Graphic formula*

DCI Recommandée

*Nom chimique ou description; Formule brute; Formule
développée*

DCI Recomendada

*Nombre químico o descripción; Fórmula molecular;
Fórmula desarrollada*

adafosbuvirum

adafosbuvir

propan-2-yl N-[(P^{5'}S)-4'-fluoro-2'-C-methyl-P-O-phenyl-5'-uridylyl]-L-alaninate


adafosbuvir

N-[(P^{5'}S)-4'-fluoro-2'-C-méthyl-P-O-phényl-5'-uridylyl]-L-alaninate de propan-2-yle

adafosbuvir

N-[(P^{5'}S)-4'-fluoro-2'-C-metil-P-O-fenil-5'-uridilil]-L-alaninato de propan-2-ilo

C₂₂H₂₉FN₃O₁₀P



adarigilinum

adarigiline

(4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)-1,2-oxazol-3-yl]thiophen-2-yl}methanone


adarigiline

(4-hydroxypipéridin-1-yl){5-[4-méthyl-5-(trifluorométhyl)-1,2-oxazol-3-yl]thiophén-2-yl}méthanone

adarigilina

(4-hidroxiopiperidin-1-il){5-[4-metil-5-(trifluorometil)-1,2-oxazol-3-il]tiofeno-2-il}metanona

C₁₅H₁₅F₃N₂O₃S



adavosertibum

adavosertib


1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3*H*-pyrazolo[3,4-*d*]pyrimidin-3-one

adavosertib

1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-méthylpipérazin-1-yl)anilino]-2-(prop-2-én-1-yl)-1,2-dihydro-3*H*-pyrazolo[3,4-*d*]pyrimidin-3-one

adavosertib

1-[6-(2-hidroxiopropan-2-il)piridin-2-il]-6-[4-(4-metilpiperazin-1-il)anilino]-2-(prop-2-en-1-il)-1,2-dihidro-3*H*-pirazolo[3,4-*d*]pirimidin-3-ona

C₂₇H₃₂N₈O₂**adimlecleucelum**

adimlecleucel

Human culture enriched allogenic Cytomegalovirus-specific cytotoxic T cells (CMV-CTL) for cell-based therapy. Cells are isolated from blood of CMV seropositive healthy human donors. CMV-CTLs exhibit human leukocyte antigen (HLA)-restricted cytotoxic activity against CMV+ cells in allogeneic hematopoietic cell or solid organ transplant patients with CMV infection.

adimlecleucel

Lymphocytes T cytotoxiques spécifiques du cytomégalovirus (CMV-CTL), allogéniques, humains, enrichis en culture pour thérapie cellulaire. Les cellules sont isolées à partir du sang de donneurs humains sains séropositifs au CMV. Les CMV-CTL montrent une activité cytotoxique restreinte à l'antigène leucocytaire humain (HLA) contre les cellules CMV+ chez des patients transplantés avec des cellules hématopoïétiques allogéniques ou avec un organe solide, et souffrants d'une infection à CMV.

adimlecleucel







Linfocitos T citotóxicos específicos del virus de Citomegalovirus (CMV-CTL), alogénicos, humanos, enriquecidos en cultivo para terapia celular. Las células están asiladas a partir de sangre de donantes humanos sanos seropositivo para CMV. Los CMV-CTLs muestran actividad citotóxica restringida por HLA contra células CMV+ en pacientes trasplantados con células hematopoyéticas alogénicas u órgano sólido con infección por CMV.

alirinetidum

alirinetide L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-L-arginine

alirinéide L-phénylalanyl-L-séryl-L-arginyl-L-tyrosyl-L-alanyl-L-arginine

alirinetida L-fenilalanil-L-seril-L-arginil-L-tirosil-L-alanil-L-arginina

**alobresibum**alobresib [2-cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1*H*-benzimidazol-4-yl]di(pyridin-2-yl)methanolalobrésib [2-cyclopropyl-6-(3,5-diméthyl-1,2-oxazol-4-yl)-1*H*-benzimidazol-4-yl]di(pyridin-2-yl)méthanolalobresib [2-ciclopropil-6-(3,5-dimetil-1,2-oxazol-4-il)-1*H*-benzimidazol-4-il]di(piridin-2-il)metanol**arfolitixorinum**arfolitixorin *N*-{4-[(6*aR*)-3-amino-1-oxo-1,2,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]pteridin-8(9*H*)-yl]benzoyl}-L-glutamic acidarfolitixorine acide *N*-{4-[(6*aR*)-3-amino-1-oxo-1,2,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]ptéridin-8(9*H*)-yl]benzoyl}-L-glutamiquearfolitixorina ácido *N*-{4-[(6*aR*)-3-amino-1-oxo-1,2,5,6,6*a*,7-hexahidroimidazo[1,5-*f*]pteridin-8(9*H*)-il]benzoil}-L-glutámico

asivatrepum

asivatrep


(2*E*)-*N*-{[(1*R*)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide

asivatrep

(2*E*)-*N*-{[(1*R*)-1-[3,5-difluoro-4-(méthanesulfonamido)phényl]éthyl]-3-[2-propyl-6-(trifluorométhyl)pyridin-3-yl]prop-2-énamide

asivatrep

(2*E*)-*N*-{[(1*R*)-1-[3,5-difluoro-4-(metanosulfonamido)fenil]etil]-3-[2-propil-6-(trifluorometil)piridin-3-il]prop-2-enamida

C₂₁H₂₂F₅N₃O₃S**atabecestatum**

atabecestat


N-{3-[(4*S*)-2-amino-4-methyl-4*H*-1,3-thiazin-4-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide

atabécestat

N-{3-[(4*S*)-2-amino-4-méthyl-4*H*-1,3-thiazin-4-yl]-4-fluorophényl}-5-cyanopyridine-2-carboxamide

atabecestat

N-{3-[(4*S*)-2-amino-4-metil-4*H*-1,3-tiazin-4-il]-4-fluorofenil}-5-cianopiridina-2-carboxamida

C₁₈H₁₄FN₅OS**atidortoxumabum #**

atidortoxumab

immunoglobulin G1-kappa, anti-[*Staphylococcus aureus* alpha toxin (AT, alpha-hemolysin, alpha-HL, hly, hla) and bi-component leukocidins (HlgAB, HlgCB, LukED, and LukSF (Panton-Valentine leukocidin, PVL)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03 [9.7.12] (1-119) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228''-231-231'')-bisdisulfide

atidortoxumab

immunoglobuline G1-kappa, anti-[*Staphylococcus aureus* toxine alpha (AT, hémolysine alpha, HL-alpha, hly, hla) et leucocidines à deux composants (HlgAB, HlgCB, LukED, LukSF (leucocidine de Pantón-Valentine, PVL))], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure

atidortoxumab

inmunoglobulina G1-kappa, anti-[*Staphylococcus aureus* toxina alfa (AT, hemolisina alfa, HL-alfa, hly, hla) y leucocidinas con dos componentes (HlgAB, HlgCB, LukED, LukSF (Pantón-Valentine leucocidina, PVL))], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLQESGPG	LVRPSETLSL	TCAVSGYSIS	SGMGWGWIQ	PPGKGLEWIG	50
SIDQRGSTYY	NPSLRSRTI	SVDTSKNQFS	LKLSSTAAAD	TAVYYCARD	100
GHAVDMDVWG	KGTTVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTWSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLMISRTP	ETCVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVSVLTV	LHQDNLNGKE	YKCKVSNKAL	PAPIETKISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEVESNGQPE	NNYKTTTPVL	400
DSDSGFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPG	448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	VSASVGDRVT	ITCRASQGIS	RWLAWYQKP	GKAPKLLIYA	50
ASSLQSGVPS	RFGSGSGTD	FTLTISLQP	EDFATYYCQ	GYVFPITFGG	100
GTKVEIKRTV	AAPSVFIAPP	SDEQLKSGTA	SVVCLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"

Intra-L (C23-C104)	23'-88'	134'-194'
	23"-88"	134"-194"

Inter-H-L (h 5-CL 126) 222-214' 222"-214"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires

complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

GOF 46%, G1F 39.9%

avadomidum


avadomide

rac-(3*R*)-3-(5-amino-2-methyl-4-oxoquinazolin-3(4*H*)-yl)piperidine-2,6-dione

avadomide

rac-(3*R*)-3-(5-amino-2-méthyl-4-oxoquinazolin-3(4*H*)-yl)pipéridine-2,6-dione

avadomida

rac-(3*R*)-3-(5-amino-2-metil-4-oxoquinazolin-3(4*H*)-il)piperidina-2,6-dionaC₁₄H₁₄N₄O₃**avalglucosidasum alfa #**

avalglucosidase alfa

mutated human acid α -glucosidase produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated to a synthetic branched hexasaccharide containing two terminal mannose-6-phosphate (M6P), via aminoxy linkers;

[His¹⁴³>Arg,Arg¹⁶⁷>His,Val⁷²⁴>Ile]prepro-lysosomal α -glucosidase (EC=3.2.1.20) (human) (57-952)-peptide, expressed in CHO cells, glycoform alfa, with 5-9 sialyl end groups of glycan residues being oxidized and chemically modified to 5-acetamido-3,5,7-trideoxy-7-[(*E*)-(2-oxo-2-{2-[4-({O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O-[O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 3)]- β -D-mannopyranosyl}oxy)butanoyl]hydrazinyl}ethoxy)imino]- β -L-arabino-2-heptulo-2,6-pyranosylonic acid groups

avalglucosidase alfa

α -glucosidase acide humaine modifiée, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, liée à un hexasaccharide de synthèse dont les résidus terminaux sont deux mannose-6-phosphates via un groupe aminoxy;

[His¹⁴³>Arg,Arg¹⁶⁷>His,Val⁷²⁴>Ile]prépro- α -glucosidase lysosomale (EC=3.2.1.20) (humaine) (57-952)-peptide, exprimé dans des cellules CHO, glycoforme alfa: 5-9 résidus sialyl terminaux sont oxydés et chimiquement modifiés en acide 5-acétamido-3,5,7-tridésoxy-7-[(*E*)-(2-oxo-2-{2-[4-({O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O-[O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 3)]- β -D-mannopyranosyl}oxy)butanoyl]hydrazinyl}éthoxy)imino]- β -L-arabino-2-heptulo-2,6-pyranosylonique

avaglucosidasa alfa

α -glucosidasa ácida humana modificada, producida en las células ováricas de hamster chino (CHO), glicoforma alfa, conjugada con un glicano hexasacárido sintético que contiene dos manosa-6-fosfatos (M6Ps) terminales, vía un grupo aminoxi;

[His¹⁴³>Arg,Arg¹⁶⁷>His,Val⁷²⁴>Ile]prepro- α -glucosidasa lisosomal (EC=3.2.1.20) (humana) (57-952)-péptido, expresada en las células CHO, glicoforma alfa: con los 5-9 restos sialil terminales están oxidados y químicamente modificados en ácido 5-acetamido-3,5,7-tridesoxi-7-[(E)-(2-oxo-2-{2-[4-({O-(6-O-fosfono- α -D-manopiranosil)-(1→2)-O- α -D-manopiranosil-(1→6)-O- α -D-manopiranosil-(1→6)-O-[O-(6-O-fosfono- α -D-manopiranosil)-(1→2)-O- α -D-manopiranosil-(1→3)]- β -D-manopiranosil]oxi)butanoil]hidrazinil}etoxi)imino]- β -L-arabino-2-heptulo-2,6-piranosilónico

Sequence / Séquence / Secuencia

```

QQGASRPGPR DAQAHGPRPR AVPTQCDVPP NSRFDCAPDK AITQECCAR 50
GCCYIPAKQG LQGAQMGPWP CFFPPSYPSY KLENLSSEM GYTATLTRTT 100
PTFFPKDILT LRLDVMETE NRLHFTIKDP ANRRYEVPLE TPRVHSRAPS 150
PLYSVFEESE PFGVIVHRQL DGRVLLNTTV APLFFADQFL QLSTSLPSQY 200
ITGLAEHLSP LMLSTSWTRI TLWNRDLAPT PGANLYGSHF FYLALEDGGS 250
AHGVFLLNSN AMDVVLQPS ALSWRSTGGI LDVYIFLGPE PKSVVQQYLD 300
VVGYPFMPYP WGLGFHLRW GYSSTAITRQ VVENMTRAHF PLDVQWMDLD 350
YMSRRDFTF NKDGFDFPA MVQELHQGGR RYMMIVDPAI SSSGPAGSYR 400
PYDEGLRRGV FITNETGQPL IGKVMGPSTA FPDFTNPATL AWMEDMVAEF 450
HDQVPFDGMW IDMNEPSNFI RGSDEGCPNN ELENPPYVPG VVGGLQAAT 500
ICASSHQFLS THYNLHNLGY LTEATASHRA LVKARGTRPF VISRSTFAGH 550
GRYAGHWTDG VSSWEQLAS SVPEILQFNL LGVPLVGADV CGFLGNTSEE 600
LCVRWTLGA FYPFMRNHS LSLPQEPYS FSEPAQQAMR KALTRLRYALL 650
PHLYTLFHQA HVAGETVARP LFLEFPKDS TWTVDHQLLW GEALLITPVL 700
QAGKAEVTGY FPLGTWYDLQ TVPIEALGSL PPPPAAPREP AIHSEGQWVT 750
LPAPLDTINV HLRAGYIPL QGPGLTTTSS RQQPMALAVA LTKGGGEARGE 800
LFWDGGSLE VLERGAYTQV IFLARNNTIV NELVRVTSEG AGLQLQKQVTV 850
LGVATAPQQV LSNVGPVSNF TYSPDTKVL D ICVSLLMGEQ FLVSWC 896

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
26-53 36-52 47-71 477-502 591-602 882-896

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-84 Asn-177 Asn-334 Asn-414 Asn-596 Asn-826 Asn-869

Methionine S-oxide / S-Oxide de méthionine / S-Óxido de metionina (~50 %)
Met-66 Met-90 Met-116 Met-117

avapritinibum
avapritinib



(1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine

avapritinib

(1S)-1-(4-fluorophényl)-1-(2-{4-[6-(1-méthyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pipérazin-1-yl}pyrimidin-5-yl)éthan-1-amine

avapritinib

(1S)-1-(4-fluorofenil)-1-(2-{4-[6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il]piperazin-1-il}pirimidin-5-il)etan-1-amina



axicabtagenum ciloleucelum #
axicabtagene ciloleucel

human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the FMC63 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (FMC63-28Z CAR). Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

axicabtagène ciloleucel

Lymphocytes T humains autologues en culture d'expansion et modifiés génétiquement pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélevé chez le patient et sont transduites avec un vecteur rétroviral non-répliquant codant pour le récepteur de l'antigène chimérique FMC63 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) CD28/CD3zêta (FMC63-28Z CAR). Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.

axicabtagén ciloleucel

Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector retroviral no replicativo que codifica para el receptor de antígenos quimérico FMC63 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) CD28/CD3zeta (FMC63-28Z CAR). Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.

beinaglutidum
beinaglutide


human glucagon-like peptide-1 (7-36)-peptide (GLP-1-(7-36))

béinaglutide

peptide 1 semblable au glucagon humain (7-36) (GLP-1-(7-36))

beinaglutida

péptido tipo 1 similar al glucagón humano (7-36) (GLP-1-(7-36))



HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR 30

bemarituzumabum #
bemarituzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, bacteria-expressed kinase, BEK, craniofacial dysostosis I, CFDI, Jackson-Weiss syndrome, JWS, CD332) isoform b (FGFR2b)], humanized monoclonal antibody;
gamma1 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), hinge (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (223-223'':226-226'')-bisdisulfide

bémarituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* FGFR2 (récepteur 2 du facteur de croissance des fibroblastes, récepteur du facteur de croissance des kératinocytes, KGFR, kinase exprimée dans des bactéries, BEK, dysostose craniofaciale I, CFDI, syndrome de Jackson-Weiss, JWS, CD332) isoforme b (FGFR2b)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-444) [VH humanisé (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), charnière (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfure avec la chaîne légère (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (223-223'':226-226'')-bisdisulfure

bemarituzumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de fibroblastos, receptor del factor de crecimiento de keratinocitos, KGFR, kinasa expresada en bacterias, BEK, disostosa craneofacial I, CFDI, síndrome de Jackson-Weiss, JWS, CD332) isoforma b (FGFR2b)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-444) [VH humanizado (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), bisagra (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfuro con la cadena ligera (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (223-223'':226-226'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SKKASGYIFT TYNVHWVRQA PGQGLEWIGS 50
 IYPDNGDTSY NQNFKGRATI TADKSTSTAY MELSSLRSED TAVYYCARGD 100
 FAYWGQGTLLV TVSSASTKGP SVFPLAPSSK STSGGTAAALG CLVKDYFPEP 150
 VTIVSNNSGAL TSGVHTFPFV LQSSGLYSLS SVTVFSSSI GTQTYICNVN 200
 HKPSNTKVDK RVEPKSCDKT HTCPCPRAPE LLGGPSVFLF PPKPRDTLMI 250
 SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV 300
 SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKARGQP REPQVYTLPP 350
 SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
 FFLYSLKLTVD KSRWQGGNVF SCSVMHEALH NHTYQKSLSL SPGR 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVIT ITCKASQGVV NDVAWYQQKPK GKAPKLLIYE 50
 ASYRYTGVPS RFSGSGSSTG DFTFTISLQP EDIATYYCQQ HSTTPYTFGQ 100
 GTKLEIKRTV AAPSVFIIPP SDEQLKSGTA SVVCLLNIFY PREAKVQWQV 150
 DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 141-197 258-318 364-422
 22"-96" 141"-197" 258"-318" 364"-422"

Intra-L (C23-C104) 23'-88" 134"-194"
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 217-214" 217"-214"

Inter-H-H (h 11, h 14) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2N84.4:

294, 294"

Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes afucosylés / glicanos de tipo CHO biantenarijos complejos afucosilados

bemcentinibum

bemcentinib


1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N³-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine

bemcentinib

1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N³-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tétrahydro-5H-benzo[7]annulén-2-yl]-1H-1,2,4-triazole-3,5-diamine

bemcentinib

1-(6,7-dihidro-5H-benzo[6,7]ciclohepta[1,2-c]piridazin-3-il)-N³-[(7S)-7-(pirrolidin-1-il)-6,7,8,9-tetrahidro-5H-benzo[7]anulen-2-il]-1H-1,2,4-triazol-3,5-diamina

C₃₀H₃₄N₈**berdazimerum natricum**

berdazimer sodium




polysodium poly[{{[3-(methylamino)propyl]silasesquioxane}-co-{{[3-(1-methyl-2-nitroso-2-oxidohydrazin-1-yl)propyl]silasesquioxane}-co-silicate (1:3:6 x)}, partially hydrolysed (Si : OH ~ 10 : 5)

berdazimère sodique

poly[[[3-(méthylamino)propyl]silasesquioxane]-co-[[3-(1-méthyl-2-nitroso-2-oxidohydrazin-1-yl)propyl]silasesquioxane]-co-silicate (1:3:6 x)] polysodique, partiellement hydrolysé (Si : OH ~ 10 : 5)

berdazímero de sodio

poli[[[3-(metilamino)propil]silasesquioxano]-co-[[3-(1-metil-2-nitroso-2-oxidohidrazin-1-il)propil]silasesquioxano]-co-silicato (1:3:6 x)] polisódico, parcialmente hidrolizado (Si : OH ~ 10 : 5)



berlimatoxumabum #
berlimatoxumab

immunoglobulin G1-kappa, anti-[*Staphylococcus aureus* LukGH (LukAB) bi-component leukocidin], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide

berlimatoxumab

immunoglobuline G1-kappa, anti-[*Staphylococcus aureus* LukGH (Luk AB) leucocidine à deux composants], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure

berlimatoxumab

inmunoglobulina G1-kappa, anti-[*Staphylococcus aureus* LukGH (Luk AB) leucocidina con dos componentes], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (CH1 (120-217), bisagra(218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

ELQLQESGPG LVKPSSETLSL TCTVSGGSIS SGSYYWDWIR QPPGKLEWI 50
 GNIYKSGSTY YNPSTKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
 RGMHYMDVWG KGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
 YFPEPVTVSW NSGALTSGVH TFPVAVLQSSG LYSLSVVTV PSSSLGTQTY 200
 ICNVNHKPSN TKVDKKVEPK SCDKTHTCP CPAPELLGPP SVFLFPPKPK 250
 DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
 TYRVSVLTIV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPV 400
 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVT ITCRASQISN SYLNWYQKPK GKAPKLLIYA 50
 ASSLQSGVPS RFSGSGSGTD FTLTISLQEP EDFATYYCQQ QFDPPFTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWQV 150
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-97 146-202 263-323 369-427
 22"-97" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23'-88' 134'-194'
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 222-214' 222"-214'"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires

complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

G0F 42.5%, G1F 39.8%

berzosertibum

berzosertib

3-(3-{4-[(methylamino)methyl]phenyl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine


berzosertib

3-(3-{4-[(méthylamino)méthyl]phényl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phényl]pyrazin-2-amine

berzosertib

3-(3-{4-[(metilamino)metil]fenil}-1,2-oxazol-5-il)-5-[4-(propano-2-sulfonyl)fenil]pirazin-2-amina

C₂₄H₂₅N₅O₃S



brexanolonum


brexanolone

3 α -hydroxy-5 α -pregnan-20-one

brexanolone

3 α -hydroxy-5 α -prègnan-20-one

brexanolona

3 α -hidroxi-5 α -pregnano-20-onaC₂₁H₃₄O₂**camidanlumabum #**

camidanlumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214'))]; dimer (224-224'':227-227'')-bisdisulfide

camidanlumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214'))]; dimère (224-224'':227-227'')-bisdisulfure

camidanlumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera

(1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":227-227")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYIINWVRQA PGQGLEWMGR 50
 IIPILGVENY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARKD 100
 WFDYWGQGTLL VTSVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
 PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVTVPSST LGTQTYICNV 200
 NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
 VSVLTVLHQD WLNKGKEYCK VSNKALPAPI EKTISKAKGQ PREPQVYTL 350
 PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
 SFFLYSKLTV DKSRWQQGNV FSCVMHEAL HNHYYTQKSL LSPGK 445

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPGT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GQAPRLIIYG 50
 ASSRATGIPD RFGSGSGSDT FTLTISRLEP EDFAVYYCQ YGSSPLTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
 LSPVTKSFN RGEK 214

Post-translational modifications
 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22"-96" 142"-198" 259"-319" 365"-423"
 22"-96" 142"-198" 259"-319" 365"-423"
 Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"
 Inter-H-L (h 5-CL 126) 218"-214" 218"-214"
 Inter-H-H (h 11, h 14) 224"-224" 227"-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 295, 295"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

camidanlumabum tesirinum # camidanlumab tesirine

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], *Homo sapiens* monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX; gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide; conjugated, on an average of 2 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)
 For the *tesirine* part, please refer to the prop.INN List 113, published in the *WHO Drug Information*, Vol.29, No.2, 2015.

camidanlumab tésirine

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticorps monoclonal conjugué au dimère de pyrrolobenzodiazépine (PDB) SCX;

camidanlumab tesirina

chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8).

Pour la partie *tesirina*, veuillez vous référer à la Liste 113 des DCI prop, publiée dans le *WHO Drug Information*, Vol.29, No.2, 2015.

immunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticuerpo monoclonal conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX;

cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro; conjugado, en una media de 2 cisteínas, al dímero de pirrolobenzodiazepina (PBD) SCX, mediante un espaciador escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida que comprende un espaciador PEG (n=8)

Para la fracción *tesirina* se puede referir a la Lista 113 de DCI prop., publicada en el *WHO Drug Information*, Vol.29, No.2, 2015.

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKPGSSVKV	SCKASGGTFS	RYIINWVRQA	PGQGLEWMGR	50
IIPILGVENY	AQKFQGRVTI	TADKSTSTAY	MELSSLRSED	TAVYYCARCKD	100
WFDYWGQGT	LVTSASTKG	PSVFPLAPSS	KSTSGGTAAL	GCLVKDYFPE	150
PVTVSWNSGA	LTSVGHFTFA	VLQSGSLYSL	SSVTVTPSSS	LGTQTYICNV	200
NHKPSNTKVD	KRVEPKSCDK	THTCPPCPAP	ELGGGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSHEDPE	VKFNWYVDGV	EVHNAKTKPR	EEQYNSTYRV	300
VSVLTVLHQD	WLNKEYKCK	VSNAKALPAP	EKTIKAKGQ	PREPQVYTL	350
PSREMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNQGPENNYK	TTPPVLDSDG	400
SFFLYSKLTV	DKSRWQGNV	FSGVMHEAL	HNHYTQKSLS	LSPGK	445

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SYLAWYQQKP	GQAPRLLIYG	50
ASSRATGIPD	RFGSGSGSDT	FTLTISRLEP	EDFAVYYCQ	YGSSPLTFGG	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200
LSPPTKSFN	RGEC				214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	142-198	259-319	365-423
	22"-96"	142"-198"	259"-319"	365"-423"

Intra-L (C23-C104)	23-88	134-194
	23"-88"	134"-194"

Inter-H-L (h 5-CL 126) *	218-214'	218"-214'"
--------------------------	----------	------------

Inter-H-H (h 11, h 14) *	224-224"	227-227'"
--------------------------	----------	-----------

*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan uno o dos puentes disulfuro inter-catenarios, una media de 2 cisteinil están conjugados con sendos enlaces tioéther, a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84,4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

canerpaturevum #

canerpaturev

Replication-competent, spontaneously occurring mutant of Herpes Simplex Virus type 1 (HSV-1) with a number of deletions and insertions in the genome, resulting in the lack of functional expression of UL43, UL49.5, UL55 and UL56.

canerpaturev

mutant spontané de Virus Herpes Simplex type 1 (HSV-1) capable de se répliquer, avec un nombre de délétions et d'insertions dans le génome, résultant en l'absence de l'expression fonctionnelle des gènes UL43, UL49.5, UL55 et UL56.

canerpaturev

Virus Herpes Simplex tipo 1 (HSV-1) competente de replicación, mutado espontáneamente, con un número de deleciones e inserciones en el genoma que dan como resultado la ausencia de expresión funcional de los genes UL43, UL49.5, UL55 y UL56.

capivasertibum

capivasertib


4-amino-*N*-[(1*S*)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(1*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide

capivasertib

4-amino-*N*-[(1*S*)-1-(4-chlorophényl)-3-hydroxypropyl]-1-(1*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)pipéridine-4-carboxamide

capivasertib

4-amino-*N*-[(1*S*)-1-(4-chlorofenil)-3-hidroxiopropil]-1-(1*H*-pirrolo[2,3-*d*]pirimidin-4-il)piperidina-4-carboxamida

$$\text{C}_{21}\text{H}_{25}\text{ClN}_6\text{O}_2$$
**cobomarsenum**

cobomarsen


all-P-ambo-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanlyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioguanlyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-methyleadenosine

cobomarsen

tout-P-ambo-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioguanilyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-O,4'-C-méthylène-P-thioguanilyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-O,4'-C-méthylène-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-O,4'-C-méthylèneadénosine

cobomarsén

todo-P-ambo-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-O,4'-C-metileno-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-O,4'-C-metileno-P-tioadenilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-2'-O,4'-C-metileneadenosina

C₁₄₈H₁₇₇N₅₂O₇₇P₁₃S₁₃(3'-5')(P-thio)(m⁵C-dA-m⁵C-dG-dA-m⁵U-m⁵U-dA-G-dC-A-m⁵U-m⁵U-A)

dX : 2'-deoxy-X / dX : 2'-désoxy-X / dX : 2'-desoxi-X

cofetuzumabum #
cofetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01, G1m17.1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (228-228":231-231")-bisdisulfide

cofétuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* PTK7 (protéine tyrosine kinase 7, kinase du cancer du côlon, CCK4) domaine extracellulaire], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (228-228":231-231")-bisdisulfure

cofetuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* PTK7 (proteína tirosina kinasa 7, kinasa del cáncer de colon, CCK4) dominio extracelular], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGPE VKKPGASVKV SCKASGYTFT DYAVHWVRQA PGKRLIEWIGV 50
ISTYNDYTYN NQDFKGRVTM TRDTSASTAY MELSLRSED TAVYYCARGN 100
SYFYALDYWG QGTSTVTSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTYSW NSGALTSGVH TFPAPVLQSSG LYSLSVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPV VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVSVLTV LHQDNLNGKE YCKVSNKAL PAPIETISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSGDSFFLYS KLTVDKSRWQ QGNVFSCSVN HEALHNHYTQ KSLSLSPG 448

```

Light chain / Chaîne légère / Cadena ligera

```

EIVLTQSPAT LSLSPGERAT LSCRASESD SYGKSFMHY QKPGQAPRL 50
LIYRASNLSE GIPARFSGSG SGTDFLTIS SLEPEDFAVY YCQSNEDPW 100
TFGGGTGLEI KRTVAAPSVF IFPPSDEQLK SGTASVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYLSL STLTLKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218

```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
 22"-96" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23'-92' 138"-198"
 23"-92'" 138'"-198"

Inter-H-L (h 5-CL 126) 222-218' 222"-218"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados.

cofetuzumabum pelidotinum #

cofetuzumab pelidotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody, conjugated to auristatin-0101; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17.1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (228-228":231-231")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to auristatin-0101 (Aur0101), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzoyloxycarbonyl (mc-val-cit-PABC) type linker

cofétuzumab pélidotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* PTK7 (protéine tyrosine kinase 7, kinase du cancer du côlon, CCK4) domaine extracellulaire], anticorps monoclonal humanisé, conjugué à l'auristatine-0101; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17.1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, à l'auristatine-0101 (Aur0101), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzoyloxycarbonyl (mc-val-cit-PABC)

cofetuzumab pelidotina

immunoglobulina G1-kappa, anti-[*Homo sapiens* PTK7 (proteína tirosina kinasa 7, kinasa de cáncer de colon, CCK4) dominio extracelular], anticuerpo monoclonal humanizado, conjugado con la auristatina-0101; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17.1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con la auristatina-0101 (Aur0101), mediante un conector escindible de tipo maleimidocaproil-valil-citrulinil-*p*-aminobenziloxycarbonil (mc-val-cit-PABC)

Heavy chain / Chaîne lourde / Cadena pesada

IQVLVQSGQE	VKKPGASVKV	SDKSGSYTF	DIYAVHHMRQA	PGKRLEWIGF	56
ISTYNDYDTYN	QQDFGKRVMT	TRTASATYAT	MELRSRSDZ	TAVVYCARGN	100
IFYALWDYWG	NQDSFVTSVA	STKGPSVFPL	APKSSKZSGG	TAALGLVKLD	150
YCPNVTVHSV	NSGALTSGVH	TKDFVLQSSG	LYALLSGLTV	PSSSLGTLGT	200
IFNNHHKPSN	TKDDKKVEPK	SPDPAWTCPP	PAELSSSVGP	SVFLFPPPKP	250
DTLISRPTVE	LTVQDWDVHG	EDPEVKFNAY	VGDEVHHNAK	TKPREEQNS	300
TRYRVSVLTV	HTCHVDYKSH	VKGFVKNYNI	PAPIETKTSK	AKQPREPQV	350
YTLPPSRDEL	TKNVTYSKRL	VGVGFPSDTA	WESHEGNOG	NNYKTPPVL	400
DSDSGFFLYS	LKLQVDSKRW	OGMVFCSFVS	HEALTHNHYTO	KSLSLSPG	448

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT	LLSLSPGERAT	LSCRASESVD	SYGKSFMHWY	QKPGGQAPRL	50
LIYRASNL	GIPIAFSGSG	SGDTFTLTIS	SLEPEDFAVY	YCQSNEDPW	100
TFGGGTLEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVCLL	NNFYPREAKV	150
QWKVDNALQ	KNSQESVTEQ	DSKDSYSTLS	STLTLSKADY	EKHKVYACEV	200
THOGLSPVPT	KSFNRGEC				218

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"


	22'-90'	140'-202'
Intra-L (C23-C104)	23'-92'	138'-198'

India-L (C23-C104)	23-92	138-198
	23 ^{III} -92 ^{III}	138 ^{III} -198 ^{III}

Inter-H-L (h 5-CL 126) * 222-218' 222"-218"

Inter-H-E (h 9, CE 120)	222-210	222-210
Inter-H-H (h 11, h 14) *	228-228"	231-231"

Modified residues / résidus modifiés / restos modificados



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaríos complejos fucosilados.

crenigacestatum
crenigacestat



4,4,4-trifluoro-*N*-[*(2S)*-1-[[*(7S)*-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5*H*-pyrido[3,2-*a*][3]benzoxazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide

crénigacestat

4,4,4-trifluoro-*N*-[*(2S)*-1-[[*(7S)*-5-(2-hydroxyéthyl)-6-oxo-6,7-dihydro-5*H*-pyrido[3,2-*a*][3]benzoxazépin-7-yl]amino]-1-oxopropan-2-yl]butanamide

crenigacestat

4,4,4-trifluoro-*N*-[[*(2S)*-1-[[*(7S)*-5-(2-idroxiutil)-6-oss-
6,7-ididro-5*H*-pidido[3,2-*a*][3]benzossazepino-7-il]amino)-
1-ossopropano-2-il]butanamida



danvatirsenum

danvatirsén


all-P-ambo-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-5-methyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-5-methyl-P-thiouridylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanynylyl-(3'→5')-2'-deoxy-P-thioguanynylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanynylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-P-thioadenylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-P-thioguanynylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-5-methylcytidine

danvatirsén

tout-P-ambo-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-5-méthyl-P-thiouridylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanynylyl-(3'→5')-2'-désoxy-P-thioguanynylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanynylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-P-thioadénylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-P-thioguanynylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-5-méthylcytidine

danvatirsén

toto-P-ambo-2'-O,4'-C-[(1S)-etano-1,1-diil]-5-metil-P-tiocitidilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-5-metil-P-tiouridilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-P-tioadenilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-P-tioguanilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-5-metilcitidina

C₁₇₂H₂₁₇N₅₆O₈₈P₁₅S₁₅(3'→5')(P-thio)(m⁵C-m⁵U-A-dT-dT-dT-dG-dG-dA-dT-dG-dT-dm⁵C-A-G-m⁵Q)

dX : 2'-deoxy-X / dX : 2'-désoxy-X

darvadstrocelum

darvadstrocel

Human culture expanded allogeneic adipose stromal progenitor cells (eASC) for cell-based therapy. Cells are derived from isolated adipose tissue of healthy living donors. eASC express cell surface markers CD29, CD73, CD90 and CD105 and are capable to express factors such as vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF- β 1), interleukin-6 (IL-6), matrix metalloproteinase inhibitor-1 (TIMP-1), and interferon-gamma (IFN- γ) inducible indoleamine 2,3-dioxygenase (IDO).

darvadstrocel

Cellules progénitrices humaines allogéniques du stroma adipeux (eASC), en culture d'expansion, pour thérapie à base de cellules. Les cellules sont dérivées d'un tissu adipeux isolé à partir de donneurs vivants sains. Les eASC expriment les marqueurs de surface CD29, CD73, CD90 et CD105 et sont capables d'exprimer les facteurs comme le facteur de croissance de l'endothélium vasculaire (VEGF), le facteur de croissance transformant beta 1 (TGF- β 1), l'interleukine 6 (IL-6), l'inhibiteur tissulaire des métalloprotéases 1 (TIMP-1) et l'indoléamine 2,3-dioxygénase (IDO) induite par l'interféron gamma (IFN- γ).

darvadstrocel

Células progenitoras del estroma adiposo alogénicas, humanas, expandidas en cultivo (eASC) para terapia celular. Las células se derivan a partir tejido adiposo aislado de donantes sanos vivos. Las eASC expresan los marcadores de superficie CD29, CD73, CD90 y CD105, y pueden expresar factores como el factor de crecimiento del endotelio vascular (VEGF), factor transformador del crecimiento beta 1 (TGF- β 1), interleukina 6 (IL-6), inhibidor de metaloproteinasas de la matriz 1 (TIMP-1), e indoleamina 2,3- dioxigenasa (IDO) inducible por interferón gamma (IFN- γ) .

davamotecanum pegadexamerum

davamotecan pegadexamer



α -acetyl- ω -{[(2*RS*)-2-hydroxypropyl]amino}poly[({[bis[(4*S*)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl] S,S'-(6',6'^{IV}-dideoxycyclomaltoheptaose-6',6'^{IV}-diyl)bis(L-cysteinylglycinate))-N^{2,1},N^{2,1}-diyl](1-oxopropane-1,3-diyl)poly(oxyethylene)oxy(3-oxopropane-1,3-diyl)]

davamotécan pégadexamère

α -acétyl- ω -{[(2*RS*)-2-hydroxypropyl]amino}poly[({[bis[(4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl] S,S'-(6',6'^{IV}-didésoxycyclomaltoheptaose-6',6'^{IV}-diyl)bis(L-cystéinylglycinate))-N^{2,1},N^{2,1}-diyl](1-oxopropane-1,3-diyl)poly(oxyéthylène)oxy(3-oxopropane-1,3-diyl)]

davamotecán pegadexámero

α -acetil- ω -{[(2*RS*)-2-hidroxiopropil]amino}poli[({[bis[(4*S*)-4-etil-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-il] S,S'-(6',6'^{IV}-didesoxiciclomaltoheptaosa-6',6'^{IV}-diil)bis(L-cisteinilglicinato))-N^{2,1},N^{2,1}-diil](1-oxopropano-1,3-diil)poli(oxietileno)oxi(3-oxopropano-1,3-diil)]

**delgocitinibum**

delgocitinib



3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

delgocitinib

3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

delgocitinib

3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

**demiplatinum pegaglumerum**

demiplatin pegaglumer



{[α-{3-[α-*N*-hydropoly(L-glutamyl-κO⁵)_m-ω-amino]propyl}-ω-méthoxypoly(oxyéthane-1,2-diyl)]_npolyato}poly[*cis*-(*SP*-4)-aquadiammineplatine(II)/*cis*-(*SP*-4)-diammineplatine(II) (x:y)], with *m* ~ 40, *n* ~ 268, *x* ~ 8, (*m*+*x*)/2 = 24

demiplatine péraglumère

{[α-{3-[α-*N*-hydropoly(L-glutamyl-κO⁵)_m-ω-amino]propyl}-ω-méthoxypoly(oxyéthane-1,2-diyl)]_npolyato}poly[*cis*-(*SP*-4)-aquadiammineplatine(II)/*cis*-(*SP*-4)-diammineplatine(II) (x:y)], avec *m* ~ 40, *n* ~ 268, *x* ~ 8, (*m*+*x*)/2 = 24

demplatino pegraglúmero

$\{[\alpha\text{-}\{3\text{-}[\alpha\text{-}N\text{-hidropoli(L-glutamyl-}\kappa\text{O}^5\text{)}_m\text{-}\omega\text{-amino}] \text{propil}\}\text{-}\omega\text{-metoxipoli(oxietano-1,2-diil)}_n\text{poliato}\}\text{poli}[cis\text{-}(SP\text{-}4)\text{-aquadiammineplatino(II)}/cis\text{-}(SP\text{-}4)\text{-diammineplatino(II)}](x:y)]$, con $m \sim 40$, $n \sim 268$, $x \sim 8$, $(m+x)/2 = 24$



$$m \sim 40, n \sim 268, x \sim 8, (m + x)/2 = 24$$

desidustatum

desidustat



N-[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl]glycine

desidustat

N-[1-(cyclopropylméthoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoléine-3-carbonyl]glycine

desidustat

N-[1-(ciclopropilmetoxi)-4-hidroxi-2-oxo-1,2-dihidroquinoleína-3-carbonil]glicina

**desmetramadolum**

desmetramadol



rac-3-[(1*R*,2*R*)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol

desmétramadol

rac-3-[(1*R*,2*R*)-2-[(diméthylamino)méthyl]-1-hydroxycyclohexyl]phénol

desmetramadol

rac-3-[(1*R*,2*R*)-2-[(dimetilamino)metil]-1-hidroxiciclohexil]fenol



and enantiomer
et énantiomère
y enantiómero

efepoetinum alfa #
efepoetin alfa

human erythropoietin (epoetin alfa) fused to a hybrid human immunoglobulin (Ig), consisting of the Fc fragment of the IgG4 fused to the hinge and amino-terminus of the IgD heavy chain isotype 2, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

[human erythropoietin (EPO) (1-166)]-[immunoglobulin heavy chain delta (IGHD) isoform 2 constant region (133-170)-peptide (C-terminal hinge region and N-terminal CH2 domain) (167-204)]-[immunoglobulin heavy chain gamma 4 (IGHG4) constant region (121-327)-peptide (CH2 and CH3 domains) (205-411)]-fusion protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

éfépoétine alfa

érythropoïétine humaine (époétine alfa) fusionnée à une immunoglobuline (Ig) humaine hybride, consistant en un fragment Fc de l'IgG4 fusionné à la région charnière et à la chaîne lourde isotype 2 de l'IgD sur la partie N-terminale, produite par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

[érythropoïétine humaine (EPO) (1-166)]-[région constante de la chaîne lourde delta de l'immunoglobuline (IGHD) isoforme 2 (133-170)-peptide (région charnière C-terminale et domaine CH2 N-terminal) (167-204)]-[région constante de la chaîne lourde de l'immunoglobuline gamma 4 (IGHG4) (121-327)-peptide (domaines CH2 et CH3) (205-411)]- protéine de fusion, produite par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efepoetina alfa

eritropoyetina humana (epoetina alfa) fusionada con una inmunoglobulina (Ig) humana híbrida, consistente en un fragmento Fc de la IgG4 fusionada con la región bisagra y con la cadena pesada isótopo 2 de la IgD sobre la parte N-terminal, producida por las células ováricas de hamster chino (CHO), glicoforma alfa;

[eritropoyetina humana (EPO) (1-166)]-[región constante de la cadena pesada delta de la inmunoglobulina (IGHD) isoforma 2 (133-170)-péptido (región bisagra C-terminal y dominio CH2 N-terminal) (167-204)]-[región constante de la cadena pesada de la inmunoglobulina gamma 4 (IGHG4) (121-327)-péptido (dominios CH2 y CH3) (205-411)]- proteína de fusión, producida por las células ováricas de hamster chinos (CHO), glicoforma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

```

APRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNIFYA 50
WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS 100
GLRSLTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR 150
GKLKLYTGEA CRTGDRRNTG RGGEKKKEK EKEEQEERET KTPECPSTHQ 200
PLGVFLFPPK PKDTLMISRT PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN 250
AKTKPREEQF NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI 300
SKAKGQPREP QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ 350
PENNYKTTTP VLSDSGSFFL YSRLTVDKSR WQEGNVFSCS VMHEALHNHY 400
TQKSLSLSLG K 411

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain disulfide bridges: 7-161 29-33 225-285 331-389
7-161' 29'-33' 225'-285' 331'-389'

Inter-chain disulfide bridges: 195-195'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-24 Asn-38 Asn-83 Asn-261

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
Ser-126

efizonerimodum alfa #
efizonerimod alfa

modified human immunoglobulin G4 Fc fragment fused to tumor necrosis factor receptor-associated factor TRAF2 (human C-C domain fragment) and to the CD252 antigen (human extracellular domain fragment), hexamer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

modified human immunoglobulin G4 Fc fragment (1-229) [*Homo sapiens*IGHG4*01 del-CH1, [10-proline (S>P)]hinge] fusion protein with human TNF receptor-associated factor2 (TRAF2)-(310-349)-peptide (230-269) fusion protein with des-(1-50)-human tumor necrosis factor ligand superfamily member4 (TNFSF4, also known as CD252 or OX40L) (270-402), produced in Chinese hamster ovary (CHO) cells, non-covalent trimer of (8-8',11-11')-bisdisulfide dimers, glycoform alfa

éfizonérimod alfa

fragment Fc modifié de l'immunoglobuline G4 humaine, fusionné au facteur associé au récepteur du facteur de nécrose tumorale TRAF2 (fragment du domaine C-C humain) et à l'antigène CD252 (fragment du domaine extracellulaire humain), hexamère, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

fragment Fc modifié de l'immunoglobuline G4 humaine (1-229)[*Homo sapiens*IGHG4*01 del-CH1, [10-proline (S>P)]charnière] protéine de fusion avec le facteur 2 associé au récepteur du TNF humain (TRAF2)-(310-349)-peptide (230-269) protéine de fusion avec le des-(1-50)-membre 4 de la superfamille des ligands du facteur de nécrose tumorale humain (TNFSF4, CD252, OX40L) (270-402), produit dans des cellules ovariennes de hamster chinois (CHO), trimère non-covalent de dimères (8-8',11-11')-bisdisulfure, glycoforme alfa

efizonerimod alfa

fragmento Fc modificado de la inmunoglobulina G4 humana, fusionada con el factor asociado al receptor del factor de necrosis tumoral TRAF2 (fragmento del dominio C-C humano) y al antígeno CD252 (fragmento del dominio extracelular humano), hexámero, producido en las células ováricas de hámsters chinos (CHO), glicofoma alfa;

fragmento Fc modificado de la inmunoglobulina G4 humana (1-229)[*Homo sapiens*IGHG4*01 del-CH1, [10-prolina (S>P)]bisagra] proteína de fusión con el factor 2 asociado al receptor del TNF humano (TRAF2)-(310-349)-péptido (230-269) proteína de fusión con el des-(1-50)- miembro 4 de la superfamilia de los ligandos del factor de necrosis tumoral humano (TNFSF4, CD252, OX40L) (270-402), producido en las células ováricas de hámster chino (CHO), trímero no-covalente de dímeros (8-8',11-11')-bisdisulfuro, glicofoma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
ESKYGPFCPP CPAEFLGGP SVLFPPKPK DTLMIERTPE VTCVVVDVSQ 50
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150
VKGIFYSDIA VEWESNGQPE NNYKTTTPVL DSDGSFFLYS RLTVDKSRWQ 200
EGNVFSCSVM HEALHNHYTQ KSLSLSLGKD QDKIEALSSK VQQLERSIGL 250
KDLAMADLEQ KVLMEASTQ VSHRYPRIQS IKVQFTEYKK EKGFIILTSQK 300
EDEIMKVQNN SVIINCDFPY LISLKGIFYSC EVNISLHYQK DEEPLQLKK 350
VRSVNSIMVA SLTYKDKVYL NVTTDNTSLD DFHVNGGELI LIHQNPGEFC 400
VL 402
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
8-8' 11-11' 43-103 149-207 316-400

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-79 Asn-309 Asn-333 Asn-371 Asn-376

eflenograstimum alfa #

eflenograstim alfa

human granulocyte-colony stimulating factor (G-CSF) fused to a hybrid human immunoglobulin consisting of the Fc fragment of the IgG4 fused to the hinge region and amino-terminus of the IgD heavy chain isotype 2, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

[human granulocyte-colony stimulating factor (G-CSF) short isoform (1-174)]-[immunoglobulin heavy chain delta (IGHD) constant region isoform 2 (133-170)-peptide (C-terminal hinge and N-terminal CH2 domains) (175-212)]-[immunoglobulin heavy chain gamma 4 (IGHG4) constant region (121-327)-peptide (CH2 and CH3 domains) (213-419)]-fusion protein, (203-203')-disulfide dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

éflénograstim alfa

facteur stimulant les colonies de granulocytes humain (G-CSF) fusionné à une immunoglobuline (Ig) humaine hybride, consistant en un fragment Fc de l'IgG4 fusionné à la région charnière et à la chaîne lourde isotype 2 de l'IgD sur la partie N-terminale, produite par des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa;

[facteur stimulant les colonies de granulocytes humain (G-CSF) isoforme courte (1-174)]-[région constante de la chaîne lourde delta de l'immunoglobuline (IGHD) isoforme 2 (133-170)-peptide (région charnière C-terminale et domaine CH2 N-terminal) (175-212)]-[région constante de la chaîne lourde de l'immunoglobuline gamma 4 (IGHG4) (121-327)-peptide (domaines CH2 et CH3) (213-419)]-protéine de fusion, (203-203')-disulfide dimère, produite par des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa

eflenograstim alfa

factor estimulante de las colonias de granulocitos humanos (G-CSF) fusionado con una inmunoglobulina (Ig) humana híbrida, consistente en un fragmento Fc de la IgG4 fusionado con la región bisagra y con la cadena pesada isótopo 2 de la IgD sobre la parte N-terminal, producido por las células ováricas de hamster chino (CHO), glicofoma alfa;

[factor estimulante de las colonias de granulocitos humanos (G-CSF) isoforma corta (1-174)]-[región constante de la cadena pesada delta de la inmunoglobulina (IGHD) isoforma 2 (133-170)-péptido (región bisagra C-terminal y dominio CH2 N-terminal) (175-212)]-[región constante de la cadena pesada de la inmunoglobulina gamma 4 (IGHG4) (121-327)-péptido (dominios CH2 y CH3) (213-419)]-proteína de fusión, (203-203')-disulfuro dímero, producido por las células ováricas de hamster chino (CHO), glicofoma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero
 TPLGASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
 GHSLGIFWAP LSSCRSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
 PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAP ASAFQRRAGG 150
 VLVASHLQSF LEVSYRVLRH LAQPRNTGRG GEEKKKEKEK EEQEERETKT 200
 PECPSHTQPL GVFLFPPKPK DTLMISRTPE VTCVVVDVSG EDPEVQFNMY 250
 VDGVEVHNAK TKFREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL 300
 PSSIEKTISK AKGQPREPQV YTLFPPSQEEM TKNQVSLTCL VKGFYPSDIA 350
 VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFCSCVM 400
 HEALHNHYTQ KSLSLSLGK 419

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-chain disulfide bridges: 36-42 64-74 233-293 339-397
 36'-42' 64'-74' 233'-293' 339'-397'
 Inter-chain disulfide bridges: 203-203'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-269

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
 Thr-133

elenbecestatum

elenbecestat


N-{3-[(4*a*S,5*R*,7*a*S)-2-amino-5-methyl-4*a*,5-dihydro-4*H*-furo[3,4-*d*][1,3]thiazin-7*a*(7*H*)-yl]-4-fluorophenyl}-5-(difluoromethyl)pyrazine-2-carboxamide

élenbécestat

N-{3-[(4*a*S,5*R*,7*a*S)-2-amino-5-méthyl-4*a*,5-dihydro-4*H*-furo[3,4-*d*][1,3]thiazin-7*a*(7*H*)-yl]-4-fluorophényl}-5-(difluorométhyl)pyrazine-2-carboxamide

elenbecestat

N-{3-[(4*a*S,5*R*,7*a*S)-2-amino-5-metil-4*a*,5-dihidro-4*H*-furo[3,4-*d*][1,3]tiazin-7*a*(7*H*)-il]-4-fluorofenil}-5-(difluorometil)pirazina-2-carboxamida

C₁₉H₁₈F₃N₅O₂S**elsulfavirinum**

elsulfavirine


N-(4-{2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetamido}-3-chlorobenzenesulfonyl)propanamide

elsulfavirine

N-(4-{2-[4-bromo-3-(3-chloro-5-cyanophénoxy)-2-fluorophényl]acétamido}-3-chlorobenzènesulfonyl)propanamide

elsulfavirina

N-(4-{2-[4-bromo-3-(3-cloro-5-cianofenoxi)-2-fluorofenil]acetamido}-3-clorobencenosulfonyl)propanamida

**emiplacelum**

emiplacel

human culture expanded allogenic adherent mesenchymal-like stromal cells for cell-based therapy. Cells are derived of maternal origin from isolated placentae of healthy donors following a cesarean section. Cells express cell surface markers CD29, CD73, and CD105 and exhibit immunomodulatory, pro-angiogenic and muscle regeneration effects.

émiplacel

cellules mésenchymales adhérentes humaines allogéniques semblables au stroma, en culture d'expansion, pour thérapie cellulaire. Les cellules d'origine maternelle sont obtenues à partir du placenta de donneuses saines et vivantes suivant une césarienne. Les cellules expriment les marqueurs de surface CD29, CD73, and CD105 et montrent des propriétés immunomodulatrices et des effets pro-angiogéniques.

emiplacel

células adherentes mesenquimales similares al estroma alogénicas, humanas, expandidas en cultivo para terapia celular. Las células de origen materno se derivan a partir de la placenta de donantes sanos vivos tras una sección por cesárea. Las células expresan los marcadores de superficie CD29, CD73 y D105, y muestran efectos inmunomoduladores y angiogénicos

enarodustatum

enarodustat



N-[7-hydroxy-5-(2-phenylethyl)[1,2,4]triazolo[1,5-*a*]pyridine-8-carbonyl]glycine

énarodustat

N-[7-hydroxy-5-(2-phényléthyl)[1,2,4]triazolo[1,5-*a*]pyridine-8-carbonyl]glycine

enarodustat

N-[7-hidroxi-5-(2-feniletíl)[1,2,4]triazolo[1,5-*a*]piridina-8-carbonil]glicina



estetrolum


estetrol

estra-1,3,5(10)-triene-3,15 α ,16 α ,17 β -tetrol

estétrol

estra-1,3,5(10)-triène-3,15 α ,16 α ,17 β -tétrol

estetrol

estra-1,3,5(10)-trieno-3,15 α ,16 α ,17 β -tetrol
$$\text{C}_{18}\text{H}_{24}\text{N}_4$$


exebacasum #

exebacase

Streptococcus suis bacteriophage-derived lysin, produced in *Escherichia coli*:

des-Met¹-phage lysin (endolysin, lysozyme, murein hydrolase, EC 3.2.1.17) of *Streptococcus suis* phage ϕ 891591 (PlySs2), produced in *Escherichia coli*

exébacase

lysine dérivée du bactériophage *Streptococcus suis*,
produite par *Escherichia coli*:

lysine du dès-Mét¹-phage *Streptococcus suis* ø891591 (PlySs2) (endolysine, lysozyme, muréine hydrolase, EC 3.2.1.17), produite par *Escherichia coli*

exebacasa

lisina derivada del bacteriófago *Streptococcus suis*,
producido por *Escherichia coli*:

lisina del des-Met¹-fago *Streptococcus suis* φ891591 (PlySs2) (endolisina, lisozima, mureína hidrolasa, EC 3.2.1.17), producida por *Escherichia coli*

Sequence / Séquence / Secuencia

TTVNEALNNV	RAQVGSQSV	GNCECYALAS	WYERMISPD	TVGLGAGVGW	50
VSGAIGDTIS	AKNIGSSYNW	QANGWTVSTS	GPFKAGQIVT	LGATPGNPYG	100
HVVIVAEVDG	DLRLTILEQN	GGKRYVPVRN	YSAASRQQV	VHYITPPGTV	150
AQSAPNLGAS	RSYRETGTMT	VTVDALNNRR	APNTSYYQV	VYKRGESFDY	200
DTVIDVNGY	VWVSYIGGSS	KRNYVATGAT	KDGKRRGNW	GTFK	244

fenebrutinibum

fenebrutinib


(6²S)-2³-(hydroxymethyl)-1⁷,1⁷,3¹,6²-tetramethyl-1³,1⁴,1⁷,1⁸-tetrahydro-4-aza-1(2)-cyclopenta[4,5]pyrrolo[1,2-a]pyrazina-6(1,4)-piperazina-2(2,4),3(3,5),5(2,5)-tripyridina-7(3)-oxetanaheptaphane-1¹(6¹H),3⁶(3¹H)-dione

fénébrutinib

(6²S)-2³-(hydroxyméthyl)-1⁷,1⁷,3¹,6²-tétraméthyl-1³,1⁴,1⁷,1⁸-
tétrahydro-4-aza-1(2)-cyclopenta[4,5]pyrrolo[1,2-
a]pyrazina-6(1,4)-pipérazina-2(2,4),3(3,5),5(2,5)-
tripyridina-7(3)-oxétanaheptaphane-1¹(1⁶H),3³(3¹H)-dione

fenebrutinib

(6²S)-2³-(hidroximetil)-1⁷,1⁷,3¹,6²-tetrametil-1³,1⁴,1⁷,1⁸-tetrahidro-4-aza-1(2)-ciclopenta[4,5]pirrolo[1,2-a]pirazina-6(1,4)-piperazina-2(2,4),3(3,5),5(2,5)-tripiridina-7(3)-oxetanaheptafano-1¹(1⁶H),3⁶(3³H)-diona

C₃₇H₄₄N₈O₄**firibastatum**

firibastat


4,4'-disulfanediybis[(3S)-3-aminobutane-1-sulfonic] acid

firibastat

acide 4,4'-disulfanediybis[(3S)-3-aminobutane-1-sulfonique]

firibastat

ácido 4,4'-disulfanodiilbis[(3S)-3-aminobutano-1-sulfónico]

C₈H₂₀N₂O₆S₄**foligluraxum**

foliglurax


N-[6-[3-(morpholin-4-yl)propyl]-2-(thieno[3,2-c]pyridin-6-yl)-4H-1-benzopyran-4-ylidene]hydroxylamine

foliglurax

N-[6-[3-(morpholin-4-yl)propyl]-2-(thieno[3,2-c]pyridin-6-yl)-4H-1-benzopyran-4-ylidene]hydroxylamine

foliglurax

N-[6-[3-(morfolin-4-il)propil]-2-(tieno[3,2-c]piridin-6-il)-4H-1-benzopiran-4-ilideno]hidroxilamina

C₂₃H₂₃N₃O₃S

fulacimstatum

fulacimstat


1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1*R*)-4-(trifluoromethyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

fulacimstat

acide 1-(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1*R*)-4-(trifluorométhyl)-2,3-dihydro-1*H*-indén-1-yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique

fulacimstat

ácido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1*R*)-4-(trifluorometil)-2,3-dihidro-1*H*-inden-1-il]-1,2,3,4-tetrahidropirimidina-5-carboxílico

C₂₃H₁₆F₃N₃O₆**garvagliptinum**

garvagliptin


(2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[5-(methanesulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]oxan-3-amine

garvagliptine

(2*R*,3*S*,5*R*)-2-(2,5-difluorophényl)-5-[5-(méthanesulfonyl)-3,4,5,6-tétrahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]oxan-3-amine

garvagliptina

(2*R*,3*S*,5*R*)-2-(2,5-difluorofenil)-5-[5-(metanosulfonyl)-3,4,5,6-tetrahidropirrol[3,4-*c*]pirrol-2(1*H*)-il]oxan-3-amina

C₁₈H₂₃F₂N₃O₃S**gimsilumabum #**

gimsilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) - (IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214'))]; dimer (230-230":233-233")-bisdisulfide

gimsilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (218) (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dimère (230-230":233-233")-bisdisulfure

gimsilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CSF2 (factor 2 estimulante de colonias (granulocito-macrófago), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (218) (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGTFES RHWMLRQV PGKGPVWSR 50
INGAGTSITY ADSVRGRFTI SRDNANNTLF LQMNSLRAD TLYFCARAN 100
SVWFRGLFDY WQGGTFVTVS SASTKGPSVF PLAPSSKSTS GGTAAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFFAVLQS SGLYSLSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GFSVFLFPFK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQFPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFPYSD IAVEWESNGQ PENNYKTTTP 400
VLDSGGSFFL YSKLTVDKSR WQQGNVFCSS VVHEALHNYH TQKSLSLSPG 450
K 451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPVT LSVSPGERVT LSCRASQSVS TNLAWYQQKL GQGPRLLIYG 50
ASTRATDIPA RFGSGGSETE FTLTISSLQS EDFAVYYCCQ YDKWPDTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQNKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"

Intra-L (C23-C104) 23'-88" 134'-194'
23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 224-214' 224"-214"

Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H VH N84

76, 76"

H CH2 N84.4:

301, 301"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaríos complejos fucosilados

ianalumabum #

ianalumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215'))]; dimer (233-233":236-236")-bisdisulfide

ianalumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF13C (membre 13C de la super famille du récepteur du facteur de nécrose tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur d'activation des lymphocytes B], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215'))]; dimère (233-233":236-236")-bisdisulfure

ianalumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF13C (miembro 13C de la super familia del receptor del factor de necrosis tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de activación de los linfocitos B], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215'))]; dímero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQQSGPG LVKPSQTLSTL TCAISGDSVS SNSAAWGWIR QSPGRGLEWL 50
 GRIYYRSKWY NSYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA 100
 RYQWVPKIGV FDSWGQGLTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
 CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSL SVVTPVSSSL 200
 GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPCPCAPE LLGGPSVFLF 250
 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
 REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
 TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKLSL 450
 SPGK 454

Light chain / Chaîne légère / Cadena ligera
 DIVLTQSPAT LSLSPGERAT LSCRASQFIL PEYLSWYQQK PGQAPRLLIY 50
 GSSSRATGVP ARFSGSGSGT DFTLTISLLE PEDFAVYYCQ QFYSSPLTFG 100
 QGTKEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNMF YPREAKVQWK 150
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TSLKADYEKH KVYACEVTHQ 200
 GLSSPVTKSF NRGE 215

Post-translational modifications
 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22"-99" 151"-207" 268"-328" 374"-432"
 22"-99" 151"-207" 268"-328" 374"-432"
 Intra-L (C23-C104) 23"-89" 135"-195"
 23"-89" 135"-195"
 Inter-H-L (h 5-CL 126) 227"-215" 227"-215"
 Inter-H-H (h 11, h 14) 233"-233" 236"-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 304, 304"
 Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes afucosylés / glicanos de tipo CHO biantenaricos complejos afucosilados
 N-terminal glutamine cyclization
 H VH Q1: 1, 1"
 C-terminal lysine clipping
 H CHS K2: 454, 454"

iberdomidum
 iberdomide

(3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione


iberdomide

(3S)-3-[4-({4-[(morpholin-4-yl)méthyl]phényl}méthoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]pipéridine-2,6-dione

iberdomida

(3S)-3-[4-({4-[(morfolin-4-il)metil]fenil}metoxi)-1-oxo-1,3-dihidro-2H-isoindol-2-il]piperidina-2,6-diona

C₂₅H₂₇N₃O₅



imlifidasum #
 imlifidase

human immunoglobulin G-degrading cysteine protease from *Streptococcus pyogenes* (IdeS, residues 30-339), produced in *Escherichia coli*;
 L-methionyl-immunoglobulin G-degrading protease (*Streptococcus pyogenes*) (IdeS) pro-protein (30-339)-peptide, produced by *Escherichia coli*

imlifidase	cystéine protéase de <i>Streptococcus pyogenes</i> dégradant l'immunoglobuline G humaine (IdeS, résidus 30-339), produite par <i>Escherichia coli</i> ; L-méthionyl-protéase dégradant l'immunoglobuline G (<i>Streptococcus pyogenes</i>) (IdeS) pro-protéine (30-339)-peptide, produite par <i>Escherichia coli</i>
imlifidasa	cisteína proteasa de <i>Streptococcus pyogenes</i> que degrada a la inmunoglobulina G humana (IdeS, residuos 30-339), producida por <i>Escherichia coli</i> ; L-metionil-proteasa que degrada la inmunoglobulina G (<i>Streptococcus pyogenes</i>) (IdeS) pro-proteína (30-339)-péptido, producido por <i>Escherichia coli</i>
Sequence / Séquence / Secuencia MDSFSANQEI RYSEVTPYHV TSVWTKGVTF PANETQGEDV FHAPYVANQG 50 WYDITKTENG KDDLLOGAAT AGNMLHWWFD QNKDQIKRYL EEHPEKQKIN 100 FNGEQMFDVK EADITKNHQL DSKLFEYFKE KAFFYLSTKH LGVFPPDHVIC 150 MFINGYRLSL TNHGTPTVKE GSKDPRGGIF DAVFTRGDQS KLLTSRHDFFK 20C EKNLKEISDL IKKELTEGKA LGLSHTYANV RINHVINLWG ADFDSNGNLK 25C AIYVTDSDSN ASIGMKKYFV GVN SAGKVAI SAKEIKEDNI GAQVLGLFTL 30C STGQDSWNQT N 311	
istiratunabum # istiratunab	immunoglobulin G1-kappa anti-[<i>Homo sapiens</i> IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], each heavy chain being fused to a scFv anti-[<i>Homo sapiens</i> ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], <i>Homo sapiens</i> monoclonal antibody, bispecific tetravalent; gamma1 heavy chain anti-IGFR1 fused to a scFv anti-ERBB3 (1-720) [<i>Homo sapiens</i> gamma1 heavy chain {(<i>Homo sapiens</i> VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117)) [8.8.15] (1-122) - <i>Homo sapiens</i> IGHG1*03v,G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), hinge (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451)) (123-451)) (1-451)-15-mer tris(tetraglycyl-seryl) linker (452-466) -scFv {(<i>Homo sapiens</i> VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4*01) [8.8.15] (467-588) -23-mer alanyl-seryl-threonyl-tetrakis(tetraglycyl-seryl) linker (589-611) - <i>Homo sapiens</i> V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glycyl (720)) (467-720)], (225-214')-disulfide with kappa light chain anti-IGFR1 (1'-214') [<i>Homo sapiens</i> V-KAPPA(IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214'))]; dimer (231-231'':234-234'')-bisdisulfide
istiratunab	immunoglobuline G1-kappa anti-[<i>Homo sapiens</i> IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R, CD221)], chaque chaîne lourde étant fusionnée à un scFv anti-[<i>Homo sapiens</i> ERBB3 (récepteur à activité tyrosine kinase erbB-3, HER3)], <i>Homo sapiens</i> anticorps monoclonal, bispécifique tétravalent; chaîne lourde gamma1 anti-IGFR1 fusionnée à un

istiratumab

scFv anti-ERBB3 (1-720) [chaîne lourde gamma1 *Homo sapiens* {(Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219)(123-220), charnière (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451))(1-451) -15-mer tris(tétraglycyl-séryl) linker (452-466)-scFv {(Homo sapiens VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4-01) [8.8.15](467-588) -23-mer alanyl-séryl-thréonil-tétrakis(tétraglycyl-séryl) linker (589-611) -Homo sapiens V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glycyl (720))(467-720)), (225-214')-disulfure avec la chaîne légère kappa anti-IGFR1 (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure

inmunoglobulina G1-kappa anti-[Homo sapiens IGF1R (receptor del factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R, CD221)], cada cadena pesada estando fusionada con un scFv anti-[Homo sapiens ERBB3 (receptor tirosina-proteína quinasa erbB-3, HER3)], *Homo sapiens* anticuerpo monoclonal, biespecífico tetravalente; cadena pesada gamma1 anti-IGFR1 fusionada con un scFv anti-ERBB3 (1-720) [cadena pesada gamma1 *Homo sapiens* {(Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219)(123-220), bisagra (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451))(1-451) -15-mer tris(tétraglicil-seril) espaciador (452-466)-scFv {(Homo sapiens VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4-01) [8.8.15](467-588) -23-mer alanil-seril-treonil-tetrakis(tetráglicil-seril) espaciador (589-611) -Homo sapiens V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glicil (720))(467-720)), (225-214')-disulfuro con la cadena ligera kappa anti-IGFR1 (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQSGGG LVQPGSSRLRL SCAASGMFES RYPMHWVROA PGKGLEWVGS 5C
ISGGSGGATPY ADSVKGRTFTI SRONSKNTLY LQMNSLFAEC TAVYYCAKDF 10C
YQILTGNACF YWGGTGTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 15C
VKDYFPEPVV VSNWNGALTS GVHTFFAVLQ SSGLYSLSSV VTFPSSSLGT 20C
QTYICNVNKK PSNTKVDKKV EPKSCDKTHT CPCEAPELL GGPSVFLFPP 25C
KPKDTLMISR TPEVTKVVDV VSHEDPEPKF NMYVDGVEVH NAKTKEREQ 30C
YNSTRVVSIV LTVLHQDKLN KGEYCKVSN KALPAPIETK ISKAKQFRE 35C
PQVYTLFESR EEMTKNQVSL TCVKGFYFES DIAVEWESNG QPENNYKTFP 40C
PVLDSGSGFF LYSKLTVDKS RWQQGNVFC SVNHEALNHH YTKSLSLSP 45C
GGGGSGGGGG SGGGGSQVQL VQSGGGLVQP GGSRLSCAA SGFTFDDYAM 50C
HWVRQAPGKG LEWVAGISWD SSGTGYADSV KGRFTISRDN AKNSLYLQMN 55C
SLRAEDTALY YCARDLGAYQ WVEGFDYWGQ GTLVTVSSAS TGGGGSGGGG 60C
SGGGSGGGGG SSYELTQDPA VSVALGQTVR ITCQGDLSRS YYASWYQKPK 65C
GQAPVLVIYG KNNRFGSIPD RFGSGTSGNS ASLTITGAQA EDEADYYCNS 70C
RDSFPGNQKVF GGGTKVTVLG 72C
```

Light chain / Chaîne légère / Cadena ligera

```
DIQNTQSESE LSASLGDRVT ITCASQGIS SYLAWYQKPK GKAPKLLIYA 5C
KSTLQSGVPS RFGSGSGTD FTLTISSLQP EDSATYYCQ YWTFPLTFGG 10C
GTKVEIKRTV AAPSVFIFPP SDEQLKSETA SVVCLINNEY PREAKVQKRV 15C
DNALQSGNSQ ESVTEQDSKD STYLSLSLTIT LSKADYEKHK VYACEVTHQS 20C
LSSPVTKSTN RGEC 21C
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430 488-562 633-698
 22"-96" 149"-205" 266"-326" 372"-430" 488"-562" 633"-698"
 Intra-L (C23-C104) 23'-88" 134'-194"
 23'''-88''' 134'''-194'''
 Inter-H-L (h 5-C126) 225-214' 225"-214"
 Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H C H2 N84.4:
 302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaríos complejos fucosilados

ladiratuzumabum #

ladiratuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody;
 gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (229-229":232-232")-bisdisulfide

ladiratuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC39A6 (membre 6 de la famille 39 des transporteurs de soluté, membre 6 de la famille 39 (transporteur d'ion métal) des transporteurs de soluté, membre 6 de la famille 39 (transporteur du zinc) des transporteurs de soluté, LIV-1)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (229-229":232-232")-bisdisulfure

ladiratuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC39A6 (miembro 6 de la familia 39 de los transportadores de soluto, miembro 6 de la familia 39 (transportador del ión metal) de los transportadores de soluto, miembro 6 de la familia 39 (transportador de zinc) de los transportadores de soluto, LIV-1)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SKASGLTIE DYYMHWVRQA PGQGLEWMGW 50
IDFENGDT EY GFKFPQGRVTM TRDTSINTAY MELSRRLSDD TAVYYCAVHN 100
AHYGTWEAYW GQGLTVTVSS ASTKGPEVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPTVS WNSGALISGV HTFPAVLQSS GLYSLSSVVT VESSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKHTCP PCPAPPELLGG PSVLEFPPKP 250
KDTLMISRTF EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VHLQDMLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTFPV 400
LDSGGSFFLY SKLTVDKSRW QQGNVFCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera

DVVMTQSFLS LFVTLGQPAS ISCRSSQSL L HSSGNTYLEW YQQRPGQSPR 50
PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVG V YFCFGSHVP 100
YTFGGGKIVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYBREAK 150
VQWQVDNALQ SGNSQESVTE QDSKDYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 219

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23'-93' 139'-199"
23"'-93"' 139"'-199"

Inter-H-L (h 5-CL 126) 223-219' 223"-219"

Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados.

ladiratuzumabum vedotinum #

ladiratuzumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzoyloxycarbonyl (mc-val-cit-PABC) type linker
For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

ladiratuzumab védotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC39A6 (membre 6 de la famille 39 des transporteurs de soluté, membre 6 de la famille 39 (transporteur d'ion métal) des transporteurs de soluté, membre 6 de la famille 39 (transporteur du zinc) des transporteurs de soluté, LIV-1)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa

ladiratuzumab vedotina

(1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproil-valyl-citrullinyl-p-aminobenziloxycarbonyl (mc-val-cit-PABC)

Pour la partie vedotina, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC39A6 (miembro 6 de la familia 39 de los transportadores de soluto, miembro 6 de la familia 39 (transportador del ión metal) de los transportadores del soluto, miembro 6 de la familia 39 (transportador del zinc) de los transportadores del soluto, LIV-1)], anticuerpo monoclonal humanizado conjugado con la auristatina E; cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, con 4 restos cisteinil, por término medio, con monometilauristatina E (MMAE), mediante un enlace de tipo maleimidocaproil-valil-citrulinil-p-aminobenziloxycarbonil (mc-val-cit-PABC)

Para la fracción vedotina, pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others".

Heavy chain / Chaîne lourde / Cadenapesada

QVQLVQSGAE VKKPGASVKV SKASGLTIE DYMHVVRQA PGQGLEWMGW 50
IDFENGDEY GPKEFGRTYM TROTSINTAY MELSLRLSDE TAVYYCAVHN 100
AHYCTWFAW QGGTLVTYSS ASTKGPSVFF LAPSKSTSG CTAALGCLVK 150
DYFPEPTVS NNSGALTSGV HTFFAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNKKPS NTKVDKKVLP KSCDKTHTCP PCPAPELLGG PSVFLFPPKE 250
KDTLMISRTPEVTCVVVDVS HEDPEVKHNK YVDGVEVHNA KTKPREEDYN 300
STYRVVSVLT VHQDWLNGK EYKCKVSNKA LPAPIEKTIS KARKGQREPO 350
VYTLPPSRDE LTKNQVSLTC LVKGFYFSDI AVEWESNGQP ENNYKITTFV 400
LDSGGSFPLY SKLTVOKSRW QQGNVFSCSV MHEALNNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadenaligera

DVYMTQSPLS LPVTLGQPAS ISCRSSQSL L HSSGNTYLEW YQORPGQSPR 50
PLIYKISTRF SGVPDRFSGS GSGDTFTLKI SRVEADGVV YYCFQGSHPV 100
YTFGGGTKVE IKRTVAAPSV FIFPPESDEQL KSGTASVCL LNNFYPREAK 150
VQWVKVDNALQ SGNSQESYTE QDSKDSYSL SSTLTLSKAO YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23"-93" 139"-199"
23"-93" 139"-199"

Inter-H-L (h 5-CL 126) * 223-219" 223"-219"

Inter-H-H (h 11, h 14) * 229-229" 232-232"

* Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

* Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

* Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados.

lanacogenum vosiparvovecum #

lanacogene vosiparvovec

Non-replicating recombinant adeno-associated virus type 5 (AAV5) vector containing a codon-optimised of the wild type human coagulation factor IX (F9, FIX) gene under the control of the liver promoter 1 (LP1).

lanacogène vosiparvovec

vecteur viral adéno-associé recombinant de type 5 (AAV5) non-répliquant contenant une version avec des codons optimisés du gène du facteur IX de coagulation de type sauvage (F9, FIX) humain sous le contrôle du promoteur LP1 des cellules hépatiques.

lanacogén vosiparvovec

Vector del Virus Adeno-asociado de serotipo 5 (AAV5) recombinante, no replicativo, que contiene una versión con codones optimizados del gen del factor de coagulación IX humano (F9, FIX) bajo el control del promotor hepático 1 (LP1).

lazertinibum

lazertinib


N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide

lazertinib

N-{5-[(4-{4-[(diméthylamino)méthyl]-3-phényl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-méthoxy-2-(morpholin-4-yl)phényl}prop-2-enamide

lazertinib

N-{5-[(4-{4-[(dimetilamino)metil]-3-fenil-1*H*-pirazol-1-il}pirimidin-2-il)amino]-4-metoxi-2-(morfolin-4-il)fenil}prop-2-enamida
C₃₀H₃₄N₈O₃

**leflutrozolum**

leflutrozole


4,4'-[fluoro(1*H*-1,2,4-triazol-1-yl)methylene]dibenzonitrile

léflutrozole

4,4'-[fluoro(1*H*-1,2,4-triazol-1-yl)méthylène]dibenzonitrile

leflutrozol

4,4'-[fluoro(1*H*-1,2,4-triazol-1-il)metileno]dibenzonitrilo

C₁₇H₁₀FN₅

lifirafenibum

lifirafenib


5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1*a*,6*b*-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

lifirafénib

5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluorométhyl)-1*H*-benzimidazol-2-yl]-1*a*,6*b*-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

lifirafenib

5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluorometil)-1*H*-benzimidazol-2-il]-1*a*,6*b*-dihidro-1*H*-ciclopropa[*b*][1]benzofuran-5-il}oxi)-3,4-dihidro-1,8-naftiridin-2(1*H*)-ona

$$\text{C}_{25}\text{H}_{17}\text{F}_3\text{N}_4\text{O}_3$$
**lona pegsomatropinum #**

lona pegsomatropin

human somatotropin (growth hormone, GH) produced in *Escherichia coli*, conjugated to a multi-arm polyethylene glycol carrier molecule;

somatotropin (human), produced by *Escherichia coli*, $N^{6,\text{Lys}}$ -substituted with one (((1*RS*)-5-[bis(6-(((3*RS*)-1-{3-[(3-[(2*RS*)-2,3-bis[ω-methoxypoly(oxyethylene)_n-α-yl]propoxy}propyl)amino]-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)sulfanyl)hexyl)amino]-1-[4-(((3-(dimethylamino)propyl)(methyl)carbamoyl)oxy)phenyl]-5-oxopentyl}oxy)carbonyl group

lona pegsomatropine

somatotropine humaine (hormone de croissance, GH) produite par *Escherichia coli*, conjuguée à une molécule transporteur multi-bras de polyéthylène glycol;

somatotropine (humaine), produite par *Escherichia coli*, substituée en $N^{6,\text{Lys}}$ par un groupe (((1*RS*)-5-[bis(6-(((3*RS*)-1-{3-[(3-[(2*RS*)-2,3-bis[ω-méthoxypoly(oxyéthylène)_n-α-yl]propoxy}propyl)amino]-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)sulfanyl)hexyl)amino]-1-[4-(((3-(diméthylamino)propyl)(méthyl)carbamoyl)oxy)phényl]-5-oxopentyl}oxy)carbonyle

lona pegsomatropina

somatotropina humana (hormona de crecimiento, GH) producida por *Escherichia coli*, conjugada a una molécula transportadora multi-bras de polietileno glicol;

somatotropina (humana), producida por *Escherichia coli*, sustituida en $N^{6,\text{Lys}}$ por un grupo (((1*RS*)-5-[bis(6-(((3*RS*)-1-{3-[(3-[(2*RS*)-2,3-bis[ω-metoxipoli(oxietileno)_n-α-il]propoxi}propil)amino]-3-oxopropil)-2,5-dioxopirrolidin-3-il)sulfanil]hexil)amino]-1-[4-(((3-(dimetilamino)propil](metil)carbamoiil}oxi)fenil]-5-oxopentil}oxi)carbonilo

Sequence / Séquence / Secuencia

FPTIPLSRFL DNAMLRARHL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT 50
 SLCFSESIPT PSNREETQOK SNLELLRISL LLIQSWLEPV QFLRSVFANS 100
 LYYGASDSNV YDLLKDEEG IQLTMGRLED GSPRTGQIFK QTYSKFDNTS 150
 HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F 191


Disulfide bridges location / Position des ponts disulfure / Posición de los puentes disulfuro
 53-165 182-189

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales

158 (~50%)

K 38,70,140,145 (~10% each)

41,168,172 (<5% each)



loncastuximabum

loncastuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody;
 gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01 [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01 [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211'))]; dimer (229-229":232-232")-bisdisulfide

loncastuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique;
 chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01 [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfure avec la chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01 [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211'))]; dimère (229-229":232-232")-bisdisulfure

loncastuximab

immunoglobulina G1-kappa, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico;
 cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01 [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01 [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211'))]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQPGAE VVKPGASVKL SCKTSGYTFT SNMHWVKQA PGQGLEWIGE 50
 IDPDSYTYNY NQNFQGKAKL TVDKSTSTAY MEVSSLSRDD TAVYYCARGS 100
 NPYYAYMDYW GQGTSTVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNHPKS NTKVDKKVEP KSCDKHTTCP PCPAPELLGG PSVFLFPPKP 250
 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VLVHQQDLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPPV 400
 LDSGDSGFFLY SKLTVDKSRW QQGNVFCSCV MHEALHNNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPA I MSASPGERV TMTCSASSGVN YMHWYQKPG TSPRRWIYDT 50
 SKLASGVPAR FSGSGSGTSLT ISISMEPE DAATYYCHQR GSYTFGGGTK 100
 LEIKRTVAAP SVFIFPPSDE QLKSGTASVV CLLNFPYPRE AKVQWKVDNA 150
 LQSGNSQESV TEQDSKDSY SLSSTLTLSK ADYEKHKVYA CEVTHQGLSS 200
 PVTKSFNRGE C 211

Post-translational modifications
 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 147-203 264-324 370-428
 22"-96" 147"-203" 264"-324" 370"-428"
 Intra-L (C23-C104) 23'-87" 131'-191"
 23'"-87'" 131'"-191'"
 Inter-H-L (h 5-CL 126) 223-211' 223"-211"
 Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 300, 300"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

loncastuximabum tesirinum #
 loncastuximab tesirine

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX; gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01 [8.8.13] (1-120) - *Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) - IGKJ1*01 [5.3.7] (1'-104') - *Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211'))]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 2 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsin B cleavage site) maleimide type linker containing a spacer PEG (n=8)
 For the *tesirine* part, please refer to the prop. INN List 113, published in the *WHO Drug Information*, Vol.29, No.2, 2015.

loncastuximab tésirine

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique conjugué au dimère de pyrrolobenzodiazépine (PBD) SCX; chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01 [8.8.13] (1-120) - *Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfure avec la

chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3(105'-211')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8)
Pour la partie *tesirina*, veuillez-vous référer à la Liste 113 des DCI prop, publiée dans le *WHO Drug Information*, Vol.29, No.2, 2015.

loncastuximab tesirina

immunoglobulina G1-kappa, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX;
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3(105'-211')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en una media de 2 cisteinil, con el dímero de pirrolobenzodiazepina (PBD) SCX, mediante un conector escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida y comprende un espaciador PEG (n=8)

Para la fracción *tesirina* se puede referir a la Lista 113 de DCI prop., publicada en el *WHO Drug Information*, Vol.29, No.2, 2015.

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQPGAE VVKFGASVKL SCKTSGYTFT SNMMHWKQA PGQGLEWIGE 50
IDPSDSYTHY NQNFQGGAKL TVDKSTSTAY MEVSSLRSDE TAVYYCARGS 100
NPFYYAMDTY GQGTSTVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVT VPSSSLGTQT 200
YICNVNHPKS NTKVDKKVEP KSCDKHTCP PCPAPELLGG PSVFLFPPKF 250
KDTLMISRTP EVTCVVVDVS HEDPEVKENW YVDGVEVRNA KTKPREEQYN 300
STYRVVSVLT VILQDQLNGK EYCKVSNKA LPAPIEKTI KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLT LKVGFPYSDI AVEWESNGQF ENNYKTTPEV 400
LSDSGSFELY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAI MSASPGERV MTCSASSGVN YMHVYQQKPG TSPRRWIYDT 50
SKLASGVFAR FSGSGGTSY SLTISSMEPE DAATYYCHQR GSYTFEGGK 100
LEIKRTVAAP SVFIFFPSDE QLKSGTASVV CLLNNFYPRE AKVQWKVDNA 150
LQSGNSQESV TEQDSKDSY SLSTLTLSK ADYERHKVYA CEVTHQGLSS 200
PVTKSFNRRGE C 211
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23-87 131-191
23"-87" 131"-191"

Inter-H-L (h 5-CL 126) * 223-211' 223"-211"

Inter-H-H (h 11, h 14) 229-229" 232-232"

*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyI being conjugated each via a thioether bond to a drug linker.

*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyI en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 2 cisteinil conjugados con sendos enlaces tioéter, a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


H CH2 N84.4:

300, 300"


Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

lumasirán

hidrógeno-*todo-P-ambo-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metil-3'-adenilato de {(2S,4R)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis-[(3-{3-{(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi}pentanamido)propil)amino]-3-oxopropoxi}metil)-6,10,18-trioxa-14-oxa-6,10,17-triazanonacosan-29-ol}-4-hidroxipirrolidin-2-il}metilo dúplex con *todo-P-ambo-2'-O-metil-P-tioadenilil-(5'→3')-2'-O-metil-P-tiocitidilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-O-metil-P-tiouridilil-(5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil-(5'→3')-2'-O-metiluridina**

C₅₃₀H₇₁₂F₁₀N₁₇₃O₃₂₀P₄₃S₆

X : 2'-deoxy-2'-fluoro-X / X̄ : 2'-desoxy-2'-fluoro-X
 X̄ : 2'-O-methyl-X / X̄ : 2'-O-méthyl-X



mardepodectum

mardepodect



2-({4-[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenoxy)methyl}quinoline

mardépodect

2-({4-[1-méthyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phénoxy)méthyl}quinoléine

mardepodect

2-({4-[1-metil-4-(piridin-4-il)-1H-pirazol-3-il]fenoxi}metil}quinoleína

**milademetanum**

milademetan



(3*R*,4*S*,5*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2"-oxo-1",2"-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide

miladémétan

(3*R*,4*S*,5*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-diméthyl-2"-oxo-1",2"-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide

milademetán

(3*R*,4*S*,5*R*)-*N*-[(3*R*,6*S*)-6-carbamoiloxan-3-il]-6"-cloro-4'-(2-cloro-3-fluoropiridin-4-il)-4,4-dimetil-2"-oxo-1",2"-dihidrodispiro[ciclohexano-1,2'-pirrolidina-3',3"-indol]-5'-carboxamida

**minesapridum**

minesapride



4-amino-5-chloro-*N*-{[(2*S*)-4-{[1-(hydroxyacetyl)piperidin-4-yl]methyl}morpholin-2-yl]methyl}-2-methoxybenzamide

minésapride

4-amino-5-chloro-*N*-{[(2*S*)-4-{[1-(hydroxyacétyl)pipéridin-4-yl]méthyl}morpholin-2-yl]méthyl}-2-méthoxybenzamide

minesaprida

4-amino-5-cloro-*N*-{[(2*S*)-4-{[1-(hidroxiacetil)piperidin-4-il]metil}morfolin-2-il]metil}-2-metoxibenzamida



miralimogenum ensolisbacum #
miralimogene ensolisbac

Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) expressing a fusion protein comprising the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100) and amino acids 35-622 of human mesothelin (MSLN) protein, under the control of the *Lm actA* (actin-assembly inducing protein precursor) promoter, and contained within an expression cassette of 2306 bp inserted at the *Lm inlB* (internalin B) locus

miralimogène ensolisbac

souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) avec double deletion, exprimant une protéine de fusion qui consiste en les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm* ActA (ActAN100) et les acides aminés 35-622 de la mésothéline humaine (MSLN), sous le contrôle du promoteur de *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine), et contenu dans une cassette d'expression de 2306 paires de bases insérée sur le locus de *Lm inlB* (internaline B).

miralimogén ensolisbac

Cepa viva atenuada recombinante, con doble delección, de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) que expresa una proteína de fusión consistente en los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100) y los amino ácidos 35-622 de la mesotelina humana (MSLN), bajo el control del promotor de *Lm actA* (precursor de la proteína inductora del ensamblaje de la actina), y contenido dentro de un casete de expresión de 2306 pares de bases insertado en el locus de *Lm inlB* (internalina B).

mirikizumabum #
mirikizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL23A (interleukin 23 subunit alpha, IL-23A, IL-23 subunit p19, IL23p19)], humanized monoclonal antibody; gamma4 heavy chain (1-441) [humanized VH (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (221-221'::224-224')-bisdisulfide

mirikizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* IL23A (interleukine 23 sous-unité alpha, IL-23A, IL-23 sous-unité p19, IL23p19)], anticorps monoclonal humanisé;

mirikizumab

chaîne lourde gamma4 (1-441) [VH humanisé (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (221-221":224-224")-bisdisulfure

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL23A (interleukina 23 subunidad alfa, IL-23A, IL-23 subunidad p19, IL23p19)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-441) [VH humanizado (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VRKPGSSVRV SCRASGYKFT RYVMHWVRQA PGQGLEWMGY 50
 INPYNDGTNY NEKFKGRVTI TADKSTSTAY MELSSLSRSED TAVYYCARNW 100
 DTGLWGQGTI VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
 PVTISWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV 200
 DHKPSNTKVD KRVESKYGPF CFPCEAPEAA GGFVFLFPP KPKDTLMISR 250
 TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
 LTVLHODWLN GKEYKCKVSN KGLPSSIEKT ISKAKGPPE PQVYTLPPSQ 350
 EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTFE PVLDSGGSFF 400
 LYSRLTVDKS RWQEGNVFSC SVMHEALHNN YTQKSLSLSL G 441

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRVT ITCKASDHIL KFLTWYQQKPK GKAPKLLIYG 50
 ATSLETGVPS RFGSGSGSTD FTLTISLQPD EDFATYYCQM YWSTPFTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSLT LTAKADYERHK VYACEVTHQG 200
 LSPFTKSFN RGEK 214

Post-translational modifications
 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 142-198 256-316 362-420
 22"-96" 142"-198" 256"-316" 362"-420"
 Intra-L (C23-C104) 23'-88" 134'-194"
 23'''-88''' 134'''-194'''
 Inter-H-L (h 5-CL126) 129-214' 129"-214"
 Inter-H-H (h 11, h 14) 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4;
 292, 292"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

mosunetuzumabum #
 mosunetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon) and *Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], humanized monoclonal antibody, bispecific;

	gamma1 heavy chain anti-CD3E (1-449) [humanized VH (<i>Homo sapiens</i>IGHV1-3*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i>IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), hinge (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfide with kappa light chain anti-CD3E (1'-219') [humanized V-KAPPA (<i>Homo sapiens</i>IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -<i>Homo sapiens</i>IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; gamma1 heavy chain anti-MS4A1 (1-452) [humanized VH (<i>Homo sapiens</i>IGHV3-23*04 (81.60%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -<i>Homo sapiens</i>IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), hinge (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfide with kappa light chain anti-MS4A1 (1'-213') [humanized V-KAPPA (<i>Homo sapiens</i>IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i>IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (228-231":231-234")-bisdisulfide
mosunétuzumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> CD3E (CD3 epsilon) et <i>Homo sapiens</i> MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal humanisé, bispécifique; chaîne lourde gamma1 anti-CD3E (1-449) [VH humanisé (<i>Homo sapiens</i>IGHV1-3*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i>IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), charnière (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfure avec la chaîne légère kappa anti-CD3E (1'-219') [V-KAPPA humanisé (<i>Homo sapiens</i>IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -<i>Homo sapiens</i>IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; chaîne lourde gamma1 anti-MS4A1 (1-452) [VH humanisé (<i>Homo sapiens</i>IGHV3-23*04 (81.60%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -<i>Homo sapiens</i>IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), charnière (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfure avec la chaîne légère kappa anti-MS4A1 (1'-213') [V-KAPPA humanisé (<i>Homo sapiens</i>IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i>IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (228-231":231-234")-bisdisulfure
mosunetuzumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> CD3E (CD3 epsilon) y <i>Homo sapiens</i> MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal humanizado, biespecífico;

cadena pesada gamma1 anti-CD3E (1-449) [VH humanizado (*Homo sapiens* IGHV1-3*01 (82.70%) - (IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), bisagra (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfuro con la cadena ligera kappa anti-CD3E (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')];

cadena pesada gamma1 anti-MS4A1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-23*04 (81.60%) - (IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), bisagra (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfuro con la cadena ligera kappa anti-MS4A1 (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (228-231":231-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3E)

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT NYYIHWVRQA PGQGLEWIGW 50
IYPGNGDTKY NEKFGRATL TADTSTSTAY LELSSLRSED TAVYYCARD 100
YSNYYFDYWG QGTLVTSSA STKGPSVPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TPAVLQSSG LYSLSVTVT PSSSLGTQTY 200
ICNVNHHKPSN TKVDKKVEPK SCDKTHCTCP CPAPELLGSP SVFLFPPKPK 250
DTLMISRTP ETCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSGDSFFLV S KLTVDKSRWQ QGNVFSCVM HEALHNHYTQ KSLSLSPGK 449
```

Light chain / Chaîne légère / Cadena ligera (anti-CD3E)

```
DIVMTQSPDS LAVSLGERAT INCKSSQSL NSTRTRKNYLA WYQKPGQPP 50
KLIIYMASTR ESGVPRDFSG SSGSDTFLT ISSLQAEDVA VYCTQSFIL 100
RTFGQGTQVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDYSTL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-MS4A1)

```
EVQLVSGGG LVQPGGSLRL SCAASGYTFT SYNHWVRQA PGKLEWVGA 50
IYPGNGDTSY NQKFKGRFTI SVDKSKNTLY LQMNSLRAED TAVYYCARV 100
YYSNSYWFYD VMGGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPVSSSLGT 200
QTYICNVNHH PSNTKVDKKV EPKSCDKTHT CPCCPAPELL GGPVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YGSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL WCLVKGFYPS DIAVEWESNG QPENNYKTTT 400
PVLSDSGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP 450
GK 452
```

Light chain / Chaîne légère / Cadena ligera (anti-MS4A1)

```
DIQMTQSPSS LSASVGRVIT ITCRASSSVS YMHYQKQPG KAPKPLIYAP 50
SNLASEGVP SR FSGSGSGTDF TLTISSLQPE DFATYYCQQW SFNPPTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLNNFYF REAKVQWQVD 150
NALQSGNSQE SVTEQDSKDS TYSLSLTLT SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 149"-205" 266"-326" 372"-430"

Intra-L (C23-C104) 23'-94' 139'-199'
23"-87" 133"-193"

Inter-H-L (h 5-CL 126) 222-219' 225"-213"

Inter-H-H (h 11, h 14) 228-231" 231-234"

nadofaragenum firadenovecum #

nadofaragene firadenovec

Replication-deficient adenovirus type 5 (Ad5) vector encoding the human interferon alpha 2 (IFNA2, interferon alpha-2b) gene under the control of the cytomegalovirus (CMV) immediate-early enhancer/promoter.

nadofaragène firadénovec

vecteur adénoviral de type 5 (Ad5) à la réplication déficiente, codant pour le gène de l'interféron alpha 2 (IFNA2, interféron alpha-2b) humain sous le contrôle de l'activateur/promoteur immédiat-précoce du cytomégalovirus (CMV).

nadofaragén firadenovec

Vector de Adenovirus tipo 5 (Ad5) deficiente de replicación, que codifica para el gen del interferón alfa 2 humano (IFNA2, inteferón alfa-2b) bajo el control del promotor/*enhancer* inmediato-temprano del citomegalovirus (CMV).

namodenosonum

namodenoson


1-(2-chloro-6-[[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-*N*-methyl-β-D-ribofuranuronamide

namodénoson

1-(2-chloro-6-[[[(3-iodophényl)methyl]amino]-9H-purin-9-yl]-1-désoxy-*N*-méthyl-β-D-ribofuranuronamide

namodenosón

1-(2-cloro-6-[[[(3-iodofenil)metil]amino]-9H-purin-9-il]-1-desoxi-*N*-metil-β-D-ribofuranuronamida

$$\text{C}_{18}\text{H}_{18}\text{ClIN}_6\text{O}_4$$
**nangibotidum**

nangibotide

human trem-like transcript 1 protein (TLT-1, triggering receptor expressed on myeloid cells-like protein 1) (79-90)-peptide 12-amide:

L-leucyl-L-glutaminy-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methioninamide


nangibotide

protéine transcrit 1 semblable au trem humaine (TLT-1, protéine 1 semblable au récepteur déclenchant exprimé par les cellules myéloïdes) (79-90)-peptide 12-amide: L-leucyl-L-glutaminy-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cystéinyl-L-méthioninamide

nangibotida

proteína transcrito 1 parecido al trem humano (TLT-1, proteína 1 parecida al receptor desencadenante expresado por las células mieloides) (79-90)-péptido 12-amida:

L-leucil-L-glutaminil-L- α -glutamyl-L- α -glutamyl-L- α -aspartil-
L-alanilglycil-L- α -glutamyl-L-tirosilglycil-L-cisteinil-
L-metioninamida



H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH₂
12

olinciguatum

olinciguat



(2*R*)-3,3,3-trifluoro-2-[[[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1*H*-pyrazol-3-yl]pyrimidin-4-yl)amino]methyl]-2-hydroxypropanamide

olinciguat

(2*R*)-3,3,3-trifluoro-2-[[[(5-fluoro-2-{1-[(2-fluorophényl)méthyl]-5-(1,2-oxazol-3-yl)-1*H*-pyrazol-3-yl]pyrimidin-4-yl)amino]méthyl]-2-hydroxypropanamide

olinciguat

(2*R*)-3,3,3-trifluoro-2-[[[(5-fluoro-2-{1-[(2-fluorofenil)metil]-5-(1,2-oxazol-3-il)-1*H*-pirazol-3-il]pirimidin-4-il)amino]metil]-2-hidroxiopropanamida



olorofimum

olorofim



2-(1,5-dimethyl-3-phenyl-1*H*-pyrrol-2-yl)-*N*-{4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl}-2-oxoacetamide

olorofim

2-(1,5-diméthyl-3-phényl-1*H*-pyrrol-2-yl)-*N*-{4-[4-(5-fluoropyrimidin-2-yl)pipérazin-1-yl]phényl}-2-oxoacétamide

olorofim

2-(1,5-dimetil-3-fenil-1*H*-pirrol-2-il)-*N*-{4-[4-(5-fluoropirimidin-2-il)piperazin-1-il]fenil}-2-oxoacetamida



omberacetamum

omberacetam


ethyl 1-phenylacetyl-L-prolylglycinate

ombéracétam

1-phénylacétyl-L-prolylglycinate d'éthyle

omberacetam

1-fenilacetil-L-prolilglicinato de etilo

 $C_{17}H_{22}N_2O_4$ **onasemnogenum abeparvovecum #**

onasemnogene abeparvovec

Non-replicating recombinant self-complementary (sc) adeno-associated viral serotype 9 (AAV9) vector containing the cDNA of the survival of motor neuron 2 (SMN2) gene under the control of the hybrid cytomegalovirus (CMV) enhancer/chicken beta-actin promoter (CBA).

onasemnogène abéparvovec

vecteur viral adéno-associé recombinant de sérotype 9 (rAAV9) non-répliquant et auto-complémentaire, contenant l'ADNc du gène de survie des motoneurones 2 (SMN2) sous le contrôle de l'hybride de l'activateur du cytomégalovirus (CMV) et du promoteur de l'actine bêta du poulet (ABP, CBA).

onasemnogén abeparvovec

vector del virus adeno-asociado de serotipo 9 (AAV9) recombinante, no replicativo y auto complementario, que contiene el cDNA del gen de la supervivencia de neuronas motoras 2 (SMN2) bajo el control del híbrido del *enhancer* de citomegalovirus (CMV) y el promotor de la beta-actina de pollo (CBA).

opaganibum

opaganib


3-(4-chlorophenyl)-N-[(pyridin-4-yl)methyl]adamantane-1-carboxamide

opaganib

3-(4-chlorophényl)-N-[(pyridin-4-yl)méthyl]adamantane-1-carboxamide

opaganib

3-(4-clorofenil)-N-[(piridin-4-il)metil]adamantano-1-carboxamida

 $C_{23}H_{25}ClN_2O$ 

opiranserinum


opiranserin

4-butoxy-*N*-[4-(dimethylamino)oxan-4-yl]methyl]-3,5-dimethoxybenzamide

opiransérine

4-butoxy-*N*-[4-(diméthylamino)oxan-4-yl]méthyl]-3,5-diméthoxybenzamide

opiranserina

4-butoxi-*N*-[4-(dimetilamino)oxan-4-il]metil]-3,5-dietoxibenzamida $C_{21}H_{34}N_2O_5$ **opolimogenum capmilibacum #**

opolimogene capmilibac

Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm* $\Delta actA/\Delta inlB$) expressing three recombinant fusion proteins as follows:

- (i) the N-terminal 100 amino acids of the *Lm* ActA (actin-assembly inducing protein precursor) protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and human protein SSX2 (synovial sarcoma, X breakpoint 2, also known as cancer/testis antigen 5.2 (CT5.2), tumor antigen HOM-MEL-40), under the control of the *Lm actA* promoter, and contained within an expression cassette of 1434 bp inserted at the *actA* locus;
- (ii) the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 33-386 of human prostatic acid phosphatase (PAP), under the control the *Lm actA* promoter, and contained within an expression cassette of 2057 bp inserted at the *inlB* (internalin B) locus;
- (iii) the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 11-234 of human homeobox protein Nkx-3.1 (NKX3-1) plus amino acids 1-20, 44-138 and 169-750 of human glutamate carboxypeptidase 2 (also known as folate hydrolase 1 (FOLH1), prostate-specific membrane antigen (PSMA)), under the control the *Lm actA* promoter, and contained within an expression cassette of 4984 bp at the *tRNA^{Arg}* locus.

opolimogène capmilibac

Souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm* $\Delta actA/\Delta inlB$) avec double délétion, exprimant les trois protéines de fusion suivantes:

- (i) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine) (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et la protéine humaine SSX2 (sarcome synovial, point de cassure X2, aussi connu comme antigène cancer/testicule 5.2 (CT5.2), antigène tumoral HOM-MEL-40), sous le contrôle du promoteur *Lm actA*, et contenu dans une cassette d'expression de 1434 paires de bases insérée sur le locus de *actA*;

opolimogén capmilibac

(ii) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 33-386 de la phosphatase acide prostatique (PAP) humaine, sous le contrôle du promoteur *Lm actA*, contenu dans une cassette d'expression de 2057 paires de bases insérée sur le locus de *inlB* (internaline B);

(iii) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 11-234 de la protéine homéoboîte humaine Nkx-3.1 (NKX3-1) plus les acides aminés 1-20, 44-138, 169-750 de la glutamate carboxypeptidase 2 humaine (folate hydrolase 1, FOLH1, antigène membranaire spécifique de la prostate, PSMA) sous le contrôle du promoteur *Lm actA*, contenu dans une cassette d'expression de 4984 paires de bases insérée sur le locus de *Lm tRNA^{Arg}*.

Cepa viva atenuada recombinante, con doble delección, de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) que expresa las siguientes tres proteínas recombinantes de fusión:

(i) los 100 amino ácidos N-terminales de la proteína *Lm ActA* (precursor de la proteína inductora del ensamblaje de la actina) (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y la proteína humana SSX2 (synovial sarcoma, X breakpoint 2, also known as cancer/testis antigen 5.2 (CT5.2), tumor antigen HOM-MEL-40), bajo el control del promotor de *Lm actA*, y contenido dentro de un casete de expresión de 1434 pares de bases insertado en el locus de *actA*;

(ii) los 100 amino ácidos N-terminales de la proteína *Lm ActA* (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 33-386 de la fosfatasa ácida prostática (PAP) humana, bajo el control del promotor de *Lm actA*, y contenido dentro de un casete de expresión de 2057 pares de bases insertado en el locus de *inlB* (internalina B);

(iii) los 100 amino ácidos N-terminales de la proteína *Lm ActA* (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 11-234 de la proteína *homeobox* humana Nkx-3.1 (NKX3-1) más los amino ácidos 1-20, 44-138 y 169-750 de la glutamato carboxipeptidasa 2 humana (también conocida como folato hidrolasa 1 (FOLH1), antígeno de membrana específico de próstata (PSMA)), bajo el control del promotor de *Lm actA* y contenido dentro de un casete de expresión de 4984 pares de bases insertado en el locus de *Lm tRNA^{Arg}*.


pamiparibum
pamiparib

(10aR)-2-fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one

pamiparib (10a*R*)-2-fluoro-10a-méthyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tétrazacyclohepta[*def*]cyclopenta[*a*]fluorén-4(7*H*)-one

pamiparib 10a*R*)-2-fluoro-10a-metil-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[*def*]ciclopenta[*a*]fluoren-4(7*H*)-ona

C₁₆H₁₅FN₄O




parsacalisib
parsacalisib

(4*R*)-4-{3-[(1*S*)-1-(4-amino-3-méthyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)éthyl]-5-chloro-2-éthoxy-6-fluorophényl}pyrrolidin-2-one

parsacalisib (4*R*)-4-{3-[(1*S*)-1-(4-amino-3-méthyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)éthyl]-5-chloro-2-éthoxy-6-fluorophényl}pyrrolidin-2-one

parsacalisib (4*R*)-4-{3-[(1*S*)-1-(4-amino-3-metil-1*H*-pirazolo[3,4-*d*]pirimidin-1-il)etil]-5-cloro-2-etoxi-6-fluorofenil}pirrolidin-2-ona

C₂₀H₂₂ClFN₆O₂



pegdarbepoetinum beta #
pegdarbepoetin beta

N-terminal pegylated human erythropoietin fragment, mutated, produced in Chinese hamster ovary (CHO) cells, glycoform beta;

[Ala³⁰>Asn, His³²>Thr, Pro⁸⁷>Val, Trp⁸⁸>Asn, Pro⁹⁰>Thr]erythropoietin (human)-(1-165)-peptide, produced in Chinese hamster ovary (CHO) cells, glycoform beta, chemically modified on Ala¹-N with a 4-[ω-methoxypoly(oxyethylene)_n-α-yl]butyl group (n ~ 682).

pegdarbépéotine bêta


fragment d'érythropoïétine humaine pégylé à l'extrémité N-terminale, modifié, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme bêta;

pegdarbepoetina beta

[Ala³⁰>Asn,His³²>Thr,Pro⁸⁷>Val,Trp⁸⁸>Asn,Pro⁹⁰>Thr]érythropoïétine (humaine)-(1-165)-peptide, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme bêta, chimiquement modifié sur l'Ala¹-N avec un groupe 4-[ω-méthoxypoly(oxyéthylène)_n-α-yl]butyle (n ~ 682).

fragmente de eritropoyetina humana pegilado en la extremidad N-terminal, modificado, producido por las células ováricas de hamster chino (CHO), glicoforma beta;

[Ala³⁰>Asn,His³²>Thr,Pro⁸⁷>Val,Trp⁸⁸>Asn,Pro⁹⁰>Thr]eritropoyetina (humana)-(1-165)-péptido, producido por las células ováricas de hamster chino (CHO), glicoforma beta, químicamente modificado sobre la Ala¹-N con un grupo 4-[ω-metoxipoli(oxietileno)_n-α-il]butilo (n ~ 682).



Sequence / Séquence / Secuencia

```


APPRLICDSR VLERYLLEAK EAENITTCGN ETCSLNENIT VPDTKVNFYA 50
WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQVNET LQLHVDKAVS 100
GLRSLTLLR ALGAQKEALS PPDAASAPL RTITADTERK LFRVYSNFLR 150
GKLRKLYTGEA CRTGD 165

```

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
7-161 29-33

Modified residue / Résidu modifié / Resto modificado

A (1) = N-pegAla



Glycosylation site (N, S) / Site de glycosylation (N, S) / Posición de glicosilación (N, S)
Asn-24 Asn-30 Asn-38 Asn-88 Asn-80 Ser-126

pegilodecakinum #
pegilodecakin

N-terminal pegylated human interleukin 10 (IL10) analogue, with an added methionine at the N-terminus, dimer, produced in recombinant *Escherichia coli*; N-[3-[ω-methoxypoly(oxyethylene)-α-yl]propyl]-L-methionyl-interleukin 10 (human), homodimer (non-covalent), produced in recombinant *Escherichia coli*

pégilodécakine

analogue de l'interleukine 10 humaine, pégylé en position N-terminale, avec l'ajout d'une méthionine en position N-terminale, dimère, produit par *Escherichia coli*; N-[3-[ω-méthoxypoly(oxyéthylène)-α-yl]propyl]-L-méthionyl-interleukine 10 (humaine), homodimère (non covalent), produit par *Escherichia coli*

pegilodecakina


análogo de la interleukina 10 humano, pegilado en posición N-terminal, con la ayuda de una metionina en posición N-terminal, dímero, producido por *Escherichia coli*; N-[3-[ω-metoxipoli(oxietileno)-α-il]propil]-L-metionil-interleukina 10 (humano), homodímero (no covalente), producido por *Escherichia coli*

Monomer sequence / Séquence du monomère / Secuencia del monómero

SPGQGTQSEN SCTHFPGNLF NMLRDLRDAF SRVKTFFQMK DQLDNLLKE 50
 SLEEDFKGYL GCQALSEMIQ FYLEEVPQA ENQDPDIKAH VNSLGENLKT 100
 LRLRLRCHRF FLPCENKSKA VEQVKNAFENK LQEKGIYKAM SEFDIFYNYI 150
 EAYMTMKIRN 160

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 12-108 62-114

Modified residues / Résidus modifiés / Restos modificados



pegzilarginasum #
 pegzilarginase

pegylated human arginine amidinase (arginase I, EC=3.5.3.1), mutated, cobalt ions replacing native manganese ions, trimer, produced in *Escherichia coli*;

des-Met¹-arginase-1 (human) dicobalt(II) complex, trimer, produced by *Escherichia coli*, substituted on an average of 8 to 16 primary amino groups of each protein monomer with [ω -methoxypoly(oxyethylene)_n- α -yl]acetyl groups (n ~ 120)

pegzilarginase

arginine amidinase humaine pégylée (arginase I, EC=3.5.3.1), modifiée, dans laquelle le manganèse est remplacé par du cobalt, trimère, produit par *Escherichia coli*;

dès-Mét¹-arginase-1 (humaine) dicobalt(II) complexe, trimère, produit par *Escherichia coli*, substituée sur une moyenne de 8 sur 16 groupes amines primaires de chaque monomère de la protéine avec des groupes [ω -méthoxypoly(oxyéthylène)_n- α -yl]acétyles (n ~ 120)

pegzilarginasa


arginina amidinasa humana pegilada (arginasa I, EC=3.5.3.1), modificada, iones de cobalto que reemplazan iones de manganeso nativos, trímero, producido por *Escherichia coli*;

des-Met¹-arginasa-1 (humana) dicobalto(II) complejo, trímero, producido por *Escherichia coli*, sustituida por una media de 8 a 16 grupos aminas primarias de cada monómero de la proteína con los grupos [ω -metoxipoli(oxietileno)_n- α -il]acetilos (n ~ 120)

Monomer sequence / Séquence du monomère / Secuencia del monómero

SAKSRTIGII GAPFSKGQPR GGVEEGPTVL RKAGLLEKLEK EQECDVKDYG 50
 DLFFADIPND SPFQIVKNPR SVGKASEQLA GKVAEVKNKG RISLVLGGDH 100
 SLAIGSISGH ARVHPDLGVI WVDÄHTDINT FLTTTSGNLH GQPVSFLLKE 150
 LKGIKIPDVPG FSWVTPCISA KDVIYIGLRD VDPGEHYILK TLGIKYFSMT 200
 EVDRLGIGKV MEETLSYLLG RKKRPIHLSF DVDGLDPSFT PATGTPVVG 250
 LTYREGLYIT EEIYKTGLLS GLDIMEVNPS LGKTPPEEVR TVNTAVAITL 300
 ACFLAREGN HKPIDYLNPP K 321

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales



pemlimogenum merolisbacum #
pemlimogene merolisbac

Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) expressing a fusion protein comprising the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 35-622 of human mesothelin (MSLN), under the control the *Lm actA* (actin-assembly inducing protein precursor) promoter, and contained within an expression cassette of 3874 bp inserted at the *Lm tRNA^{Arg}* locus.

pemlimogène mérolisbac

Souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) avec double délétion, exprimant une protéine de fusion qui consiste en les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm* ActA (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 35-622 de la mésothéline humaine (MSLN), sous le contrôle du promoteur de *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine), et contenu dans une cassette d'expression de 3874 paires de bases insérée sur le locus de *Lm tRNA^{Arg}*.

pemlimogén merolisbac

Cepa viva atenuada recombinante, con doble deleción, de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) que expresa una proteína de fusión consistente en los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 35-622 de la mesotelina humana (MSLN), bajo el control del promotor de *Lm actA* (precursor de la proteína inductora del ensamblaje de la actina), y contenido dentro de un casete de expresión de 3874 pares de bases insertado en el locus de *Lm tRNA^{Arg}*.

petesicatibum
petesicatib



(2*S*,4*R*)-*N*-(1-cyanocyclopropyl)-4-[4-(1-methyl-1*H*-pyrazol-4-yl)-2-(trifluoromethyl)benzenesulfonyl]-1-[1-(trifluoromethyl)cyclopropane-1-carbonyl]pyrrolidine-2-carboxamide

pétésicatib

(2*S*,4*R*)-*N*-(1-cyanocyclopropyl)-4-[4-(1-méthyl-1*H*-pyrazol-4-yl)-2-(trifluorométhyl)benzènesulfonyl]-1-[1-(trifluorométhyl)cyclopropane-1-carbonyl]pyrrolidine-2-carboxamide

petesicatib

2*S*,4*R*)-*N*-(1-cianociclopropil)-4-[4-(1-metil-1*H*-pirazol-4-il)-2-(trifluorometil)bencenosulfonil]-1-[1-(trifluorometil)ciclopropano-1-carbonil]pirrolidina-2-carboxamida

**pixatimodum**

pixatimod


5α-cholestan-3β-yl 2,3,4,6-tetra-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-β-D-glucopyranoside

pixatimod

2,3,4,6-tétra-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-β-D-glucopyranoside de 5α-cholestan-3β-yle

pixatimod

2,3,4,6-tetra-O-sulfo-α-D-glucopiranosil-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopi-ranosil-(1→4)-2,3,6-tri-O-sulfo-β-D-glucopiranosida de 5α-colestan-3β-ilo

**plocabulinum**

plocabulin



(1Z,4S,6Z)-1-[(2S)-2-[(2Z,4Z,6E,8S)-8-[(2S)-5-methoxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-6-methylnona-2,4,6-trienamido]-3,3-dimethylbutanamido]octa-1,6-dien-4-yl carbamate

plocabuline

carbamate de (1Z,4S,6Z)-1-[(2S)-2-[(2Z,4Z,6E,8S)-8-[(2S)-5-méthoxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-6-méthylnona-2,4,6-triénamido]-3,3-diméthylbutanamido]octa-1,6-dien-4-yle

plocabulina

carbamato de (1Z,4S,6Z)-1-[(2S)-2-[(2Z,4Z,6E,8S)-8-[(2S)-5-metoxi-6-oxo-3,6-dihidro-2H-piran-2-il]-6-metilnona-2,4,6-trienamido]-3,3-dimetilbutanamido]octa-1,6-dien-4-ilo



prasinezumabum #
prasinezumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* SNCA (synuclein alpha, PARK1, PARK4, Parkinson disease (autosomal dominant, Lewy body) 4, alpha-synuclein, aSyn, non A4 component of amyloid precursor, NACP)], humanized monoclonal antibody;
gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), hinge (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (225-225'':228-228'')-bisdisulfide

prasinezumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* SNCA (synucléine alpha, PARK1, PARK4, maladie de Parkinson (autosomique dominante, corps de Lewy) 4, synucléine-alpha, aSyn, composant non A4 du précurseur amyloïde, NACP)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), charnière (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfure avec la chaîne légère (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (225-225'':228-228'')-bisdisulfure

prasinezumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* SNCA (sinucleína alfa, PARK1, PARK4, enfermedad de Parkinson (autosómica dominante, cuerpos de Lewy) 4, sinucleína-alfa, aSyn, componente no A4 del precursor amiloide, NACP)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), bisagra (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfuro con la cadena ligera (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYGMSWVRQA FGKGLEWVAS 50
 ISSGGGSTYY PDNVKGRFTI SRDDAKNSLY LQMNSLRAED TAVVYCARGG 100
 AGIDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
 EPTVTSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
 VNHKPSNTKV DKRVEPKSCD KHTCTPCPA PELLGGPSVF LFPPKPKDTL 250
 MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
 VVSVLTVLHQ DWLNGKEYKC KVSNAKLPAP IKTISKAKG QPREPQVYTL 350
 PPSREMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTFPVLDS 400
 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGDRVT ITCKSIQTLT YSSNQKNYLA WFQKPGKAP 50
 KLLIYWASIR KSGVPSRFSG SGSSTGDTFLT ISSLQPEDLA TYQCQQYYSY 100
 PLTFGGGKTL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNFPYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSYTS LSSTLTLSKA DYEKHKVYAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 260-320 366-424
 22"-96" 143"-199" 260"-320" 366"-424"

Intra-L (C23-C104) 23"-94" 140"-200"
 23""-94"" 140""-200""

Inter-H-L (h 5-CL 126) 219-220" 219"-220"

Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

296, 296"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

ralanitenum

ralaniten


(2R)-3-[4-(2-{4-[(2S)-3-chloro-2-hydroxypropoxy]phenyl}propan-2-yl)phenoxy]propane-1,2-diol

ralaniten

(2R)-3-[4-(2-{4-[(2S)-3-chloro-2-hydroxypropoxy]phényl}propan-2-yl)phénoxy]propane-1,2-diol

ralaniten

(2R)-3-[4-(2-{4-[(2S)-3-cloro-2-hidroxipropoxi]fenil}propan-2-il)fenoxi]propano-1,2-diol

 $C_{21}H_{27}ClO_5$ **ravulizumabum #**

ravulizumab

immunoglobulin G2-4-kappa, anti-[*Homo sapiens* C5 (complement 5)], humanized monoclonal antibody; gamma2-4 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), hinge (221-232), CH2 1.6-1.1 (233-237)) (123-237) - *Homo sapiens* IGHG4*01 (CH2 1-125 (238-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (238-448)], (146-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide

ravulizumab

immunoglobuline G2-4-kappa, anti-[*Homo sapiens* C5 (complément 5)], anticorps monoclonal humanisé; chaîne lourde gamma2-4 (1-448) [VH humanisé (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), charnière (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (240-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (240-448)], (146-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*0, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":225-225":228-228":231-231")-tétrakisdisulfure

ravulizumab

immunoglobulina G2-4-kappa, anti-[*Homo sapiens* C5 (complemento 5)], anticuerpo monoclonal humanizado; cadena pesada gamma2-4 (1-448) [VH humanizado (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), bis (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (240-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (240-448)], (146-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*0, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":225-225":228-228":231-231")-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SKASGHIFS NYWIQWVRQA PGQGLEWMGE 50
ILPGSGHTEY TENFKDRYTM TRDTSTSTVY MELSSLRSSE TAVYYCARYF 100
FGSSPNWYFD VWGQGLTIVT SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFFAVLQ SSGLYSLSSV VTFVSSNFGT 200
QTYTCNVDPK PSNTKVDKTV ERKCCVECP CFAFPVAGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWVY DGEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPEVLC 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVLH EALHSHYTQK SLSLSLGK 448

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGRDVT ITCGASENIY GALNWYQKPK GKAPKLLIYG 50
ATNLADGVPS RFGSGSGGTD FTLTISSLQF EDFATYYCQN VLNTPLTFGQ 100
GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 149"-205" 262"-322" 368"-426"

22"-96" 149"-205" 262"-322" 368"-426"

Intra-L (C23-C104) 23"-88" 134"-194"

23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 136-214' 136"-214"

Inter-H-H (h 4, h 5, h 8, h 11) 224-224" 225-225" 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

redasemtium


redasemtide

human high mobility group protein B1 (HMG-1)-(1-44)-peptide (including Met¹), chemically synthesized (without any modified residues)

rédiaseptide

protéine B1 du groupe à haute mobilité humaine (HMGB1)-(1-44)- peptide (incluant Met¹), synthétisé chimiquement (sans aucun résidu modifié)

redasemtida

proteína B1 del grupo de alta movilidad humana (HMGB1)-(1-44)-péptido (incluyendo Met¹), sintetizado químicamente (sin restos modificados)

Sequence / Séquence / Secuencia

MGKGDPPKKPR GKMSYAFFV QTCREEHKKK HPDASVNFSE FSKK 44

relmapirazinum



relmapirazin

N,N'-(3,6-diaminopyrazine-2,5-dicarbonyl)di-D-serine

relmapirazine

N,N'-(3,6-diaminopyrazine-2,5-dicarbonyl)di-D-sérine

relmapirazina

N,N'-(3,6-diaminopirazina-2,5-dicarbonil)di-D-serina**reloxaliasum #**


reloxaliase

oxalate decarboxylase (OxdC, EC=4.1.1.2, *Bacillus subtilis* gene yvrK), hexamer, produced in *Escherichia coli*

réloxiase

oxalate décarboxylase (OxdC, EC=4.1.1.2, gène yvrK de *Bacillus subtilis*), hexamère, produit par *Escherichia coli*

reloxaliasa

oxalate decarboxilasa (OxdC, EC=4.1.1.2, gén yvrK de *Bacillus subtilis*), hexámero, producido por *Escherichia coli*

Monomer sequence / Séquence du monomère / Secuencia del monómero

```

MKKQNDIPQF IRGDKGATVK IPRNIERDRQ NPDMLVPPET DHGTVSNMKF 50
SFSDTHNRLE KGGYAREVTV RELPISENLA SVNRLKPGA IRELHWHKEA 100
EWAYMIYGSA RVTIVDEKGR SFIDDVGEED LWYFPGSLPH SIQALEEGAE 150
FLLVFDDGSP SENSTFQLTD WLAHTPKVEI AANFGVTKEE ISNLPGKEKY 200
IFENQLPGSL KDDIVEGPNG EVYPPTTYRL LEQEPISSEG GKVYIADSTN 250
FKVSKTIASA LVTVEPGAMR ELHWHFNTHE WQYIISGKAR MTFVASDGAH 300
RTFNYQAGDV GYVPFAMGHY VENIGDEPLV FLEIFKDDHY ADVSLNQWLA 350
MLPETFVQAH LDLGKDFDTV LSKEKHPVVK KKCSK 355

```

remlarsenum

remlarsen





(2*RS*)-3-[[6-(cholest-5-en-3 β -yloxy)hexyl]oxy]-2-hydroxypropyl hydrogen 2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-3'-adenylate duplex with *all-P-ambo-P*-thiouridylyl-(5'→3')-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorouridine

remlarsen

hydrogéo-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-3'-adénylate de (2*RS*)-3-[[6-(cholest-5-én-3 β -yloxy)hexyl]oxy]-2-hydroxypropyle duplex avec *tout-P-ambo-P*-thiouridylyl-(5'→3')-*P*-thiouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorouridine

remlarsén

hidrógeno-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanylyl-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-3'-adenilato de (2*RS*)-3-[[6-(colest-5-en-3 β -iloxi)hexil]oxi]-2-hidroxiopropilo dúplex con *todo-P-ambo-P*-tiouridilil-(5'→3')-*P*-tiouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-guanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorouridina



rezafungini acetat
rezafungin acetate



$N^{5,1},6$ -anhydro[(4*R*,5*R*)-4-hydroxy-2-[3⁴-(pentyloxy)[1¹,2¹:2⁴,3¹-terphenyl]-1⁴-carboxamido]-5-[2-(trimethylazaniumyl)ethyl]-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3*S*,4*S*)-3-hydroxy-4-methyl-L-proline]acetate

acétate de rézafungine

acétate de $N^{5,1},6$ -anhydro[(4*R*,5*R*)-4-hydroxy-2-[3⁴-(pentyloxy)[1¹,2¹:2⁴,3¹-terphényl]-1⁴-carboxamido]-5-[2-(triméthylazaniumyl)éthyl]-L-ornithyl-L-thréonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-(4-hydroxyphényl)-L-thréonyl-L-thréonyl-(3*S*,4*S*)-3-hydroxy-4-méthyl-L-proline]

acetato de rezafungina

acetato de $N^{5,1},6$ -anhidro[(4*R*,5*R*)-4-hidroxi-2-[3⁴-(pentiloxi)[1¹,2¹:2⁴,3¹-terfenil]-1⁴-carboxamido]-5-[2-(trimetilazaniumil)etil]-L-ornitil-L-treonil-*trans*-4-hidroxi-L-prolil-(4*S*)-4-hidroxi-4-(4-hidroxiifenil)-L-treonil-L-treonil-(3*S*,4*S*)-3-hidroxi-4-metil-L-prolina]





riamilovirum
riamilovir

7-(methylsulfonyl)-3-nitro[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4(1*H*)-one

riamilovir 7-(méthylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(1*H*)-one

riamilovir 7-(metilsulfanil)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(1*H*)-ona





rivoceranibum

rivoceranib *N*-[4-(1-cyanocyclopentyl)phenyl]-2-[[pyridin-4-yl)méthyl]amino}pyridine-3-carboxamide

rivocéranib *N*-[4-(1-cyanocyclopentyl)phényl]-2-[[pyridin-4-yl)méthyl]amino}pyridine-3-carboxamide

rivoceranib *N*-[4-(1-cianociclopentil)fenil]-2-[[piridin-4-il)metil]amino}piridina-3-carboxamida




rivogenlecleucelum #

rivogenlecleucel

Human culture expanded genetically modified allogenic T cells for cell-based therapy. Cells are derived from isolated blood of a healthy human donor chosen by available HLA match (haploidentical up to fully matched) and are transduced with a Gibbon ape leukemia virus (GaV) pseudotyped gammaretroviral vector carrying an inducible caspase 9 suicide transgene and a truncated CD19 marker gene allowing selection, and a drug binding domain consisting of human FK506 (tacrolimus)-binding protein (FKBP12) with an F36V mutation. Cells exhibit anti-infective activity as adjunctive T-cell therapy in combination with allogenic hematopoietic stem cell transplantation, in combination with an inducible suicide mechanism in the event of donor T-cell induced graft versus host disease (GvHD).

rivogenlecleucel

Lymphocytes T humains allogéniques, en culture d'expansion et modifiés génétiquement en vue d'une thérapie cellulaire. Les cellules sont dérivées du sang prélevé chez un donneur sain choisi pour sa compatibilité HLA (de haploidentique à correspondant totalement) et sont transduites avec un vecteur rétroviral gamma


	pseudotypé virus de la leucémie du singe Gibbon (GaV) transportant un transgène suicide inducible de la caspase 9 et un gène CD19 tronqué comme marqueur permettant la sélection, ainsi qu'un domaine de liaison médicamenteuse consistant en la protéine humaine (FKBP12) se liant au tacrolimus (FK506) avec une mutation F36V. Les cellules montrent une activité anti-infectieuse comme thérapie adjuvante de lymphocytes T en association avec la transplantation de cellules souches hématopoïétiques allogéniques, en association aussi avec un mécanisme suicide inducible en cas de réaction du greffon contre l'hôte (GVH) induit par les lymphocytes T du donneur.
rivogenlecleucel	Linfocitos T alogénicos, humanos, expandidos en cultivo y modificados genéticamente para terapia celular. Las células se derivan a partir de sangre aislada de un donante humano sano elegido por su compatibilidad HLA (desde haploidéntico hasta totalmente coincidente) y están transducidas con un vector gamma-retroviral seudotipado del virus de la leucemia de monos Gibbon (GaV) que porta un transgen inducible suicida de caspasa 9 y un gen CD19 truncado como marcador que permite la selección, y un dominio de unión a drogas consistente en la proteína de unión al tacrólimus (FK506) humana (FKBP12) con una mutación F36V. Las células muestran actividad anti-infecciosa en terapia adyuvante de linfocitos T en combinación con trasplante alogénico de células madre hematopoyéticas, en combinación con un mecanismo suicida inducible en caso de enfermedad injerto contra huésped (EICH) inducida por los linfocitos T del donante.
rovazolacum	
rovazolac	ethyl {5-[3'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazol-1-yl}acetate
rovazolac	{5-[3'-(méthanesulfonyl)[1,1'-biphényl]-4-yl]-3-(trifluorométhyl)-1H-pyrazol-1-yl}acétate d'éthyle
rovazolac	{5-[3'-(metanosulfonyl)[1,1'-bifenil]-4-il]-3-(trifluorometil)-1H-pirazol-1-il}acetato de etilo
	$\text{C}_{21}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_4\text{S}$ 
seliforantum	
seliforant	6-[3-(methylamino)azetidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine

séliforant

6-[3-(méthylamino)azétidin-1-yl]-2-(2-méthylpropyl)pyrimidin-4-amine

seliforant

6-[3-(metilamino)azetidín-1-il]-2-(2-metilpropil)pirimidín-4-amina

 $C_{12}H_{21}N_5$ setrusumabum #
setrusumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* SOST (sclerostin)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), hinge (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (219-219":220-220":223-223":226-226")-tetrakisdisulfide

sétrusumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* SOST (sclérostine)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), charnière (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure

setrusumab

immunoglobulina G2-lambda, anti-[*Homo sapiens* SOST (esclerostina)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), bisagra (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (219-219":220-220":223-223":226-226")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG LVQPGGSLRL SCAASGFTFR SHWLSWVRQA PGKGLEWVSN 50
 INYDGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDT 100
 YLHPDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGGLVKDYF 150
 PEFVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVPS SNFGTQTYTC 200
 NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
 RTPEVTCVVV DVSHEDEPVQ FNWYVDGVEV HNAKTKPREE QFNSTFRVVS 300
 VLTVVHQDWL NGKEYKCKVQ NKGLPAPIEK TISKTKGQPR EPQVYTLPPS 350
 REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQFENNYKTT PPMLEDSGSF 400
 FLYSKLTVDK SRWQGNVFS CSVMHEALHN HYTKSLSLS PGK 443

Light chain / Chaîne légère / Cadena ligera

DIALTQPASV SGSPGQSITI SCTGTSSDVG DINDVSWYQQ HPGKAPKIMI 50
 YDVNNRPSGV SNRFGSGSKG NTASLTISGL QAEDEADYYC QSYAGSYLSE 100
 VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
 VAWKADSSPV KAGVETTFPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200
 THEGSTVEKT VAPTECS 217

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 257-317 363-421
 22"-96" 144"-200" 257"-317" 363"-421"

Intra-L (C23-C104) 22'-90' 139'-198'
 22"-90" 139"-198"

Inter-H-L (CH1 I0-CL I26) 131-216' 131"-216"

Inter-H-H (h 4, h 5, h 8, h 11) 219-219' 220-220" 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

293, 293"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

spartalizumabum #
 spartalizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;
 gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dimer (223-223":226-226")-bisdisulfide

spartalizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé;
 chaîne lourde gamma4 (1-443) [VH humanisé (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dimère (223-223":226-226")-bisdisulfure

espartalizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;

cadena pesada gamma4 (1-443) [VH humanizado (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dímero (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVQSGAE VKKPGESLRI SCKGSGYFTI TYWMHWVRQA TGQGLEWMGN 50
 IYPGTGGSNF DEKFKNRVTI TADKSTSTAY MELSSLRSED TAVYYCTRWI 100
 TGTGAYWGGQ TTVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
 PEPFVTSNNS GALTSGVHTF PAVLQSSGLY SLSSVTVPS SSLGKTKYTC 200
 NVDHKPSNTK VDKRVEVKYG PPCPFCEAPE FLGGPSVLEF PPKPKDTIMI 250
 SRTPEVTCVV VDVSEDEPEV QFNWYVDGVE VHNAKTKPRE EQENSTYRVV 300
 SVLTVLHQDW LMGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLFP 350
 SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TTPVLDSDGS 400
 FFLYSRLTVC KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLG 443

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPAT LSLSPGERAT LSKSSQSLI DSGNQKNFLT WYQKPGQAP 50
 RLLIYWASTR ESGVPSRFESG SGSGTDFFTI ISSLEAEDAA TYQCNDYSY 100
 PYTFGGQTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKSTYS LSSTLTLSKA DYKHKVYAC 200
 EVTHQGLSP VTKSFNRGEC 220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 144"-200" 258"-318" 364"-422"

22"-96" 144"-200" 258"-318" 364"-422"

Intra-L (C23-C104) 23"-94" 140"-200"

23"-94" 140"-200"

Inter-H-L (h 5-CL 126) 131"-220" 131"-220"

Inter-H-H (h 11, h 14) 223"-223" 226"-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84,4:

294, 294"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

sultimotidum alfa

sultimotide alfa

a fusion protein consisting of fragments of hepatitis B virus transcription factor X, large S-protein antigen (envelope antigen), B antigen (core antigen) and of a C-terminal six-histidine tag, expressed by engineered whole heat-killed *Saccharomyces cerevisiae*, glycoform alfa;

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-(des-(69-83)-[P⁵⁹>F]pro-tein X (hepatitis B virus)-(52-127)-peptide (9-69))-
 {[M¹>E, G³>Q, Q¹⁰>K, P¹⁹S, G³⁵>R, N³⁹>A, H⁵¹>T, P⁶⁵>L, T⁸⁶>Q, A⁹¹>N]large S protein (hepatitis B virus) (70-243))-
 {[T⁴>I, V²⁵>I, N²⁰⁷>S, L²⁰⁹>V, L²¹³>I]small S protein (hepatitis B virus) (244-469))-[des-Met¹-[S¹²>T]capsid protein (hepatitis B virus) (470-651))-His₆ (652-657) fusion protein, produced in *Saccharomyces cerevisiae*, glycoform alfa

sultimotide alfa

protéine de fusion consistant en des fragments du facteur X de transcription du virus de l'hépatite B, de l'antigène de la grande protéine S (antigène de l'enveloppe), antigène B (antigène core) et d'un fragment de 6 histidines, produite par une souche de *Saccharomyces cerevisiae* inactivée par la chaleur, glycoforme alfa:

sultimotida alfa

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-{dès-(69-83)-
[P⁵⁹>F]pro-téine X (virus de l'hépatite B)-(52-127)-peptide
(9-69))-
{[M¹>E,G³>Q,Q¹⁰>K,P¹⁹S,G³⁵>R,N³⁹>A,H⁵¹>T,P⁶⁵>L,T⁸⁶>Q,
A⁹¹>N]grande protéine S (virus de l'hépatite B) (70-243))-
{[T⁴>I,V²⁵>I,N²⁰⁷>S,L²⁰⁹>V,L²¹³>I]petite protéine S (virus de
l'hépatite B) (244-469))-(dès-Mét¹-[S¹²>T]protéine de la
capside (virus de l'hépatite B) (470-651))-His₆ (652-657)
protéine de fusion, produite par *Saccharomyces
cerevisiae*, glycoforme alfa

proteína de fusión consistente en los fragmentos del factor
X de transcripción del virus de la hepatitis B, del antígeno
de la proteína S grande (antígeno de la envoltura),
antígeno B (antígeno nuclear) y de un fragmento de 6
histidinas, producida por una cepa de *Saccharomyces
cerevisiae* inactivada por el calor, glicofoma alfa:

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-{des-(69-83)-
[P⁵⁹>F]proteína X (virus de la hepatitis B)-(52-127)-
péptido)-
{[M¹>E,G³>Q,Q¹⁰>K,P¹⁹S,G³⁵>R,N³⁹>A,H⁵¹>T,P⁶⁵>L,T⁸⁶>Q,
A⁹¹>N]proteína S grande (virus de la hepatitis B))-
{[T⁴>I,V²⁵>I,N²⁰⁷>S,L²⁰⁹>V,L²¹³>I]proteína S pequeña (virus
de la hepatitis B))-(des-Met¹-[S¹²>T]proteína de la cápside
(virus de la hepatitis B))-His₆ proteína de fusión, producida
por *Saccharomyces cerevisiae*, glicofoma alfa

Sequence / Séquence / Secuencia

```
MADEAPTSHL SLRGLFVCAF SSAGPNAHQF LPKVLHKRTL GLSAMSTTDL 50
EAYFKDCLEK DWELGEELE GQWSSKPRKG MGTNLSVSNF LGFFFDHQLD 100
PAFRANSANF DWDFNPNKDI WPEANQGVVG AFGLGFTFFH GGLLGWSFOA 150
QGILQTVFAN PPPASTNRQS GRQPTFISPP LRDSHFQAMQ WNSTTFHQAL 200
LDPVRVGLYF PAGGSSSGTV NPVPTTASPI SSIFSRGTGP ALNMENITSG 250
FLGPLLVLOA GFFLLTRILT IPQSLDSWWT SLNFLGGTTT CPGQNSQSFT 300
SNHSPTSQCP ICFGYRWML RRFIIFLFIL LLCLIFLLVL LDYQGMLEVC 350
PLLPGTSTTS TGPCKTCTIP AQGTSMFPSC CTKFSDGNC TCIPIPSSWA 400
FARFLWEWAS VRFSLWLLV PFVQWVGLS PTVWLSVIMW MWYWGFSLYS 450
IVSPFIPLE IFFCLWVYID IDPYKEFGAT VELLSEFLPSD FFPSVRDLSD 500
TASALYREAL ESPEHCSPHH TALRQAILCW GELMNLATWV GSNLEDPASR 550
ELVVSYNVN MGLKIRQLLW FHISCLTFGR ETVLEYLVSE GVWIRTPPAY 600
RPFNAPILST LPETTVVRRR GRSPFRRTPS FRRRRSQSFR RRRSQSRESQ 650
CHHHHHH 657
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
18-350 57-308 291-319 312-529 333-380
364-367 381-390 382-392 464-651 516-575

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-84 Asn-192 Asn-246 Asn-302 Asn-389

tabelecleucelum
tabelecleucel

Human culture enriched allogenic Epstein-Barr virus-
specific cytotoxic T cells (EBV-CTL) for cell-based therapy.
Cells are isolated from blood of EBV seropositive healthy
human donors. EBV-CTLs exhibit human leukocyte
antigen (HLA)-restricted cytotoxic activity against EBV+
cells in allogeneic hematopoietic cell transplant patients
with EBV associated post-transplant lymphoproliferative
disease.

tabélecleucel	Lymphocytes T cytotoxiques spécifiques du virus d'Epstein-Barr (EBV-CTL), allogéniques, humains, enrichis en culture pour thérapie cellulaire. Les cellules sont isolées à partir du sang de donneurs humains sains séropositifs à l'EBV. Les EBV-CTL montrent une activité cytotoxique restreinte à l'antigène leucocytaire humain (HLA) contre les cellules EBV+ chez des patients transplantés avec des cellules hématopoïétiques allogéniques souffrants d'un syndrome lymphoprolifératif associé à l'EBV post-transplantation.
tabelecleucel	Linfocitos T citotóxicos específicos del virus de Epstein-Barr (EBV-CTL), alogénicos, humanos, enriquecidos en cultivo para terapia celular. Las células están asiladas a partir de sangre de donantes humanos sanos seropositivo para EBV. Los EBV-CTLs muestran actividad citotóxica restringida por HLA contra células EBV+ in pacientes trasplantados con células hematopoyéticas alogénicas con enfermedad linfoproliferativa post-trasplante asociada a EBV.
talacotuzumabum # talacotuzumab	immunoglobulin G1-2-kappa, anti-[<i>Homo sapiens</i> IL3RA (interleukin 3 receptor subunit alpha, interleukin 3 receptor alpha (low affinity), CD123)], humanized monoclonal antibody; gamma1-2 heavy chain (1-450) [humanized VH (<i>Homo sapiens</i> IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -hinge (219-233) -CH2 1.6-1.1 (234-239)) (121-239) - <i>Homo sapiens</i> IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (229-229":232-232")-bisdisulfide
talacotuzumab	immunoglobuline G1-2-kappa, anti-[<i>Homo sapiens</i> IL3RA (sous-unité alpha du récepteur de l'interleukine 3, récepteur alpha (faible affinité) de l'interleukine 3, CD123)], anticorps monoclonal humanisé; chaîne lourde gamma1-2 (1-450) [VH humanisé (<i>Homo sapiens</i> IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -charnière (219-233) -CH2 1.6-1.1 (234-239))(121-239) - <i>Homo sapiens</i> IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1, V101 (114'-220')]; dimère (229-229":232-232")-bisdisulfure

talacotuzumab

inmunoglobulina G1-2-kappa, anti-[*Homo sapiens* IL3RA (subunidad alfa del receptor de la interleukina 3, receptor alfa (baja afinidad) de la interleukina 3, CD123)], anticuerpo monoclonal humanizado; cadena pesada gamma1-2 (1-450) [VH humanizado (*Homo sapiens* IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -bisagra (219-233) -CH2 1.6-1.1 (234-239)) (121-239) -*Homo sapiens* IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1, V101 (114'-220')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCKGSGYSFT DYYMKWARQM PGKGLEWMD 50
IIPSNQATFY NQKFKGQVTI SADKSIITTY LQWSSLKASD TAMYCARSH 100
LLRASWFAYW GQGTMTVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTYS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKFS NTKVDKKVEP KSCDKTHICP PCPAPPELLGG PDVFLFPPKP 250
KDTLMISRTF EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STFRVSVLT VVHGDWLNKG EYKCKVSNKA LPAPPEKTI SRTKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTFPM 400
LDSGGSFELY SKLTVDKSRW QQGNVFSCSV MHEALHNYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCESSQSLL NSGNQKNYLT WYQQKPGQPP 50
KPLIYWASTR ESGVPDRFSG SGSSTDFTLT ISSLQAEDVA VYYCQNDYSY 100
PYTFGQGTKL EIKRITVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKSTYS LSSTLTLSKA DYKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23"-94" 140"-200"

23"-94" 140"-200"

Inter-H-L (h 5-CL 126) 223"-220" 223"-220"

Inter-H-H (h 11, h 14) 229"-229" 232"-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados.

tasadenoturevum #
tasadenoturev

Conditionally replicating adenovirus (CRAd) serotype 5 carrying a 24-bp deletion in early E1A gene and insertion of an integrin-binding motif (Arg-Gly-Asp) (RGD) motif into the H1 loop of the fiber knob.

tasadénoturev

adénovirus de sérotype 5 dont la réplication est conditionnelle et portant une délétion de 24 paires de bases sur le gène précoce E1A et l'insertion d'un motif d'union à l'intégrine dans la boucle H1 du *knob* de la fibre

tasadenoturev

Adenovirus de serotipo 5, con replicación condicionada, portando una delección de 24 pares de bases en el gen temprano E1A y la inserción de un motivo de unión a integrina (Arg-Gly-Asp) (RGD) en el bucle H1 del *knob* de fibra

tasipimidinum

tasipimidine


rac-2-[(1*R*)-5-methoxy-3,4-dihydro-1*H*-2-benzopyran-1-yl]-4,5-dihydro-1*H*-imidazole

tasipimidine

rac-2-[(1*R*)-5-méthoxy-3,4-dihydro-1*H*-2-benzopyran-1-yl]-4,5-dihydro-1*H*-imidazole

tasipimidina

rac-2-[(1*R*)-5-metoxi-3,4-dihidro-1*H*-2-benzopiran-1-il]-4,5-dihidro-1*H*-imidazol

 $C_{13}H_{16}N_2O_2$
**telacebecum**

telacebec


6-chloro-2-ethyl-*N*-[(4-{4-(trifluoromethoxy)phenyl}piperidin-1-yl)phenyl)methyl]imidazo[1,2-*a*]pyridine-3-carboxamide

télacébec

6-chloro-2-éthyl-*N*-[(4-{4-(trifluorométhoxy)phényl}pipéridin-1-yl)phényl)méthyl]imidazo[1,2-*a*]pyridine-3-carboxamide

telacebec













6-cloro-2-etil-*N*-[(4-{4-(trifluorometoxi)fenil}piperidin-1-il)fenil)metil]imidazo[1,2-*a*]piridina-3-carboxamida

 $C_{29}H_{28}ClF_3N_4O_2$
**temavirsenum**

temavirsén

[(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis[{3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)methyl]-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl]-4-hydroxypyrrolidin-2-yl)methyl hydrogen *all*-*P*-ambo-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl

	-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiouridylyl-(3'→5')-<i>P</i>-thiothymidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioguanilyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiouridylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiothymidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]cytidylyl-(3'→5')-2'-deoxy-3'-adenylate
témavirsén	hidrogéno-<i>tout-P-ambo</i>-2'-O-(2-méthoxyéthyl)-<i>P</i>-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-<i>P</i>-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-<i>P</i>-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiouridylyl-(3'→5')-<i>P</i>-thiothymidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioguanilyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiouridylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioadénylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioadénylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioadénylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiothymidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]cytidylyl-(3'→5')-2'-désoxy-3'-adénylate de [(2<i>S</i>,4<i>R</i>)-1-{1-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-5-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]méthyle
temavirsén	hidrógeno-<i>todo-P-ambo</i>-2'-O-(2-metoxietil)-<i>P</i>-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-<i>P</i>-thioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-<i>P</i>-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiouridilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiouridilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioadenilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-thiocytidylyl-(3'→5')-2'-desoxi-<i>P</i>-tioadenilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]citidilil-(3'→5')-2'-desoxi-3'-adenilato de [(2<i>S</i>,4<i>R</i>)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi)metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oi]-4-hidroxiipirrolidin-2-il]metilo



tibilizumabum # tibilizumab

immunoglobulin G4-kappa anti-[*Homo sapiens* TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLYS, B cell activating factor, B lymphocyte activator, CD257)], each heavy chain being fused to a scFv anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody, bispecific tetravalent; gamma4 heavy chain anti-TNFSF13B fused to a scFv anti-IL17A (1-714) [gamma4 heavy chain {(*Homo sapiens* VH (IGHV4-34*01 (100.00%) - (IGHD) -IGHJ4*01) [8.7.17] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), hinge S10>P (231) (222-233), CH2 (234-343), CH3L125>del (344-447), CHS G1>del, K2>del) (124-447))} (1-447) -16-mer linker (448-463) -scFv {(humanized VH (*Homo sapiens* IGHV1-69*01 (83.70%) - (IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tetra(tetraglycyl-seryl) linker (583-602) -humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714))} (464-714)], (137-214')-disulfide with kappa light chain anti-TNFSF13B (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229":232-232")-bisdisulfide

tibilizumab

immunoglobuline G4-kappa anti-[*Homo sapiens* TNFSF13B (membre 13B de la superfamille des facteurs de nécrose tumorale (TNF), BAFF, THANK, TALL1, TALL-1, BLYS, BLYS, facteur d'activation des lymphocytes B, activateur des lymphocytes B, CD257)], chaque chaîne lourde étant fusionnée à un scFv anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé, bispécifique tétravalent;

chaîne lourde gamma4 anti-TNFSF13B fusionnée à un scFv anti-IL17A (1-714) [chaîne lourde gamma4 {(Homo sapiens VH (IGHV4-34*01 (100.00%) (IGHD) -IGHJ4*01) [8.7.17] (1-123) -Homo sapiens IGHG4*01 (CH1 (124-221), charnière S10>P (231) (222-233), CH2 (234-343), CH3 L125>del (344-447), CHS G1>del, K2>del) (124-447))} (1-447) -16-mer linker (448-463) -scFv {(VH humanisé (Homo sapiens IGHV1-69*01 (83.70%) (IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tétra(tétraglycyl-séryl) linker (583-602) -V-KAPPA humanisé (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714))} (464-714)], (137-214')-disulfure avec la chaîne légère anti-TNFSF13B (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229":232-232")-bisdisulfure

tibulizumab

inmunoglobulina G4-kappa anti-[Homo sapiens TNFSF13B (miembro 13B de la superfamilia de los factores de necrosis tumoral (TNF), BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, factor de activación de linfocitos B, activador de linfocitos B, CD257)], cada cadena pesada estando fusionada con un scFv anti-[Homo sapiens IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado, biespecífico tetravalente; cadena pesada gamma4 anti-TNFSF13B fusionada con un scFv anti-IL17A (1-714) [cadena pesada gamma4 {(Homo sapiens VH (IGHV4-34*01 (100.00%) (IGHD) -IGHJ4*01) [8.7.17] (1-123) -Homo sapiens IGHG4*01 (CH1 (124-221), bisagra S10>P (231) (222-233), CH2 (234-343), CH3 L125>del (344-447), CHS G1>del, K2>del) (124-447))} (1-447) -16-mer de conexión (448-463) -scFv {(VH humanizado (Homo sapiens IGHV1-69*01 (83.70%) (IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tetra(tetraglicil-seril) linker (583-602) -V-KAPPA humanizado (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714))} (464-714)], (137-214')-disulfuro con la cadena ligera anti-TNFSF13B (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

OVQLGQWAG LLKPSETLSL TCAVYGGSF GYVSWIRDP PGKLEWIGE 5C
INHSGSTNIN PSLKSRVTIS VDTSKNQFSL KLSVTAADT AVYYCARGYY 100
DILTGYYVYF DYWGQGLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSNWNGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 20C
TKTYTCNVDR KPSMTKVDKR VESKYGFPCP PCPAEFLGG PSVLFPPKP 25C
KDTLMISRTPT EVTCVVVDVS QEDPEVGFENW YVDGVEVHNA KTKPREEDFN 30C
STYRVSVLT VLHQDWLNGK EYCKVKVSKG LPSSIEKTI KAKGQPREPQ 35C
VYTLPPSQEE MTRNQVSLIC LVKGIFYPSD AVENESNGQP ENNYKITPPV 40C
LQSGGSFFLY SRLTVDRSRW QEGNVFSCSV MHEALHNYH QKSLSLSPGG 45C
GSGGGGGTGG GGSQVQLVDS GAELVKRFGSS VRVSCRASGY KFTDVIHWV 50C
RQAFQGCLEW MGVINPTYG TDYKRFKGR VTIADESTS TAMELSLRL 55C
SDTAIVYICA RYDTEGTGV YWGGQGLTVR SSGGGSGGG GSGGGSGGG 60C
GSDIWMGTGF LSLSVTPGQF ASISCRSSRS LVHSRGETYL HWVLQKPGQS 65C
PQLLIYKVSN RFIGVPPDRFS GSGSGDTFTL KISRVEADV GVYYCSQSTH 70C
LPPTFGCGTK LEIK 714

```

Light chain / Chaîne légère / Cadena ligera

```

EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD 5C
ASNPRATGIPA RFGSGSGSDT SLTISSLEP EDFAVYYCQQ RSNWPRTFSQ 100
GTKVEIKRTV AAPSVFIIPP SDEQLKSGTA SVVCLLNIFY BREAKVQKV 150
DNALQSGNSG ESVTEQDSKD STYSLSLTIL LSKADYEKHK VYACEVTHQG 20C
LSSPVTKSFN RGEK 214

```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104, except for *) 22-93 150-206 264-324 370-428
 485-559 507-707* 625-695
 22'-95" 150"-206" 264"-334" 370"-428"
 485"-559" 507"-707"* 625"-695"

Intra-L (C23-C104) 23'-88" 134"-194"
 23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 137-214' 137"-214"

Inter-H-H (h 8, h 11) 229-229' 232-232"

*Disulfide bridge between the scFv VHC49 (507, 507') and V-KAPPA C120 (707, 707')

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

HCH2 N84.4:

300-300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

tigilanoli tiglas

tigilanol tiglate


(1*aR*,1*bR*,1*cS*,2*aR*,3*S*,3*aS*,6*aS*,6*bR*,7*R*,8*R*,8*aS*)-3,3*a*,6*b*-trihydroxy-2*a*-(hydroxymethyl)-1,1,5,7-tetramethyl-4-oxo-1,1*a*,1*b*,1*c*,2*a*,3,3*a*,4,6*a*,6*b*,7,8-dodecahydro-8*aH*-cyclopropa[5',6']benzo[1',2':-7,8]azuleno[5,6-*b*]oxirene-8,8*a*-diyl 8*a*-[(2*S*)-2-methylbutanoate] 8-[(2*E*)-2-methylbut-2-enoate]

tiglate de tigilanol

8*a*-[(2*S*)-2-méthylbutanoate] et 8-[(2*E*)-2-méthylbut-2-énoate] de
(1*aR*,1*bR*,1*cS*,2*aR*,3*S*,3*aS*,6*aS*,6*bR*,7*R*,8*R*,8*aS*)-3,3*a*,6*b*-trihydroxy-2*a*-(hydroxyméthyl)-1,1,5,7-tétraméthyl-4-oxo-1,1*a*,1*b*,1*c*,2*a*,3,3*a*,4,6*a*,6*b*,7,8-dodécahydro-8*aH*-cyclopropa[5',6']benzo[1',2':7,8]azuléno[5,6-*b*]oxirène-8,8*a*-diyle

toglato de tigilanol

8*a*-[(2*S*)-2-metilbutanoato] y 8-[(2*E*)-2-metilbut-2-enoato] de (1*aR*,1*bR*,1*cS*,2*aR*,3*S*,3*aS*,6*aS*,6*bR*,7*R*,8*R*,8*aS*)-3,3*a*,6*b*-trihidroxi-2*a*-(hidroximetil)-1,1,5,7-tetrametil-4-oxo-1,1*a*,1*b*,1*c*,2*a*,3,3*a*,4,6*a*,6*b*,7,8-dodécahidro-8*aH*-ciclopropa[5',6']benzo[1',2':7,8]azuleno[5,6-*b*]oxireno-8,8*a*-diilo

C₃₀H₄₂O₁₀**tigolanerum**

tigolaner


2-chloro-*N*-(1-cyanocyclopropyl)-5-[2'-methyl-5'-(pentafluoroethyl)-4'-(trifluoromethyl)-2'-*H*-[1,3'-bipyrazol]-4-yl]benzamide

tigolaner

2-chloro-*N*-(1-cyanocyclopropyl)-5-[2'-méthyl-5'-(pentafluoroéthyl)-4'-(trifluorométhyl)-2'-*H*-[1,3'-bipyrázol]-4-yl]benzamide

tigolaner

2-cloro-*N*-(1-cianociclopropil)-5-[2'-metil-5'-(pentafluoroetil)-4'-(trifluorometil)-2'-*H*-[1,3'-bipirázol]-4-il]benzamida

C₂₁H₁₃ClF₈N₆O

	le contrôle de l'hybride de l'activateur du cytomégalo­virus (CMV) et du promoteur de l'actine bêta du poulet (ABP, CBA).
timrepigén emparovéc	Vector no replicativo del Virus Adeno-asociado de serotipo 2 (rAAV2) que codifica el cDNA de la proteína escolta Rab 1 (CHM, REP-1) humana, impulsado por el híbrido del <i>enhancer</i> de citomegalovirus (CMV) y el promotor de la beta-actina de pollo (CBA).
tiragolumabum # tiragolumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-456) [<i>Homo sapiens</i> VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) - <i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), hinge (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfide with kappa light chain (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (235-235'':238-238'')-bisdisulfide
tiragolumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> TIGIT (immunorécepteur des lymphocytes T avec domaine Ig et ITIM, membre 9 de l'Ig V-set, VSIG9, membre 3 de l'Ig V-set et région transmembrane, VSTM3)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) - <i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), charnière (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfure avec la chaîne légère (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (235-235'':238-238'')-bisdisulfure
tiragolumab	immunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> TIGIT (immunoreceptor de linfocitos T con dominio Ig e ITIM, miembro 9 de la Ig V-set, VSIG9, miembro 3 de la Ig V-set y región transmembrana, VSTM3)], <i>Homo sapiens</i> anticuerpo monoclonal; cadena pesada gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) - <i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), bisagra (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfuro con la cadena ligera (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (235-235'':238-238'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLQQSGPG LVKPSQTLSTL TCAISGDSVS SNSAANNIR QSPSRGLEWL 50
 GKTYRFRKMY SDYAVSVKRG ITINPDTSKN QFSLQLNSVT PEDTAVFYCT 100
 RESTTYDLIA GPFDYWGQGT LVTSSASTK GPSVFPLAPS SKSTSGGTAA 150
 LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
 SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA FELLGGPSVF 250
 LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNAKALPAP IEKTISKAKG 350
 QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY 400
 KTTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMEHA LHNHYTQKSL 450
 SLSPGK 456

Light chain / Chaîne légère / Cadena ligera
 DIVMTQSPDS LAVSLGERAT INCKSSQTVL YSSNNKKYLA WYQQKPGQFP 50
 NLLIYWASTR ESGVPDRFSG SSGSTDEFTL ISSLQAEDVA VYYCQYYST 100
 PFTFGPGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSSTYS LSSTLTLSKA DYEKHKVYAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Post-translational modifications
 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-99 153-209 270-330 376-434
 22"-99" 153"-209" 270"-330" 376"-434"
 Intra-L (C23-C104) 23'-94' 140"-200"
 23'"-94'" 140'"-200'"
 Inter-H-L (h 5-CL 126) 229-220" 229"-220"
 Inter-H-H (h 11, h 14) 235-235" 238-238"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 306, 306"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

tirvalimogenum teraplasmidum # tirvalimogene teraplasmid

plasmid DNA vector encoding E6 and E7 antigens of human papillomavirus types 16 and 18 (HPV 16/18), the extracellular domain of *fms*-like tyrosine kinase-3 ligand (FLT3L) and signal sequences of tissue plasminogen activator (tpa) driven by a cytomegalovirus promoter.

tirvalimogène téraplasme

vecteur constitué d'ADN plasmidique codant pour les antigènes E6 et E7 des papillomavirus humains de types 16 et 18 (VPH 16/18), le domaine extracellulaire du ligand de la tyrosine kinase 3 semblable au *fms* (FLT3L) et les séquences signal de l'activateur tissulaire du plasmogène (tpa) sous le contrôle d'un promoteur de cytomégalovirus.

tirvalimogén teraplásmido

Vector de DNA plasmídico que codifica los antígenos E6 y E7 de los tipos 16 y 18 del virus del papiloma humano (VPH 16/18), el dominio extracelular del ligando de la tirosina quinasa-3 similar a *fms* (FLT3L) y secuencias señal del activador de plasminógeno tisular (tpa) impulsado por un promotor de citomegalovirus.

tisagenlecleucelum # tisagenlecleucel

human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative lentiviral vector encoding an FMC63 anti-CD19 single chain variable fragment (scFv) 4-1BB/CD3zeta chimeric antigen receptor (CAR) under the control of the EF-1 alpha promoter. Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

tisagenlecleucel	Lymphocytes T autologues humains en culture d'expansion, modifiés génétiquement en vue d'une thérapie génique avec cellules. Les cellules sont isolées à partir du sang prélevé chez le patient et sont transduites avec un vecteur lentiviral non-répliquant codant pour le récepteur de l'antigène chimérique (CAR) FMC63 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) 4-1BB/CD3zêta (SFG-1928z CAR) sous le contrôle du promoteur EF-1 alpha. Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.
tisagenlecleucel	Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector lentiviral no replicativo que codifica para el receptor de antígenos quimérico (CAR) FMC63 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) 4-1BB/CD3zeta bajo el control del promotor EF-1 alfa. Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.
tislelizumabum # tislelizumab	immunoglobulin G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain (1-445) [humanized VH (<i>Homo sapiens</i> IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) - <i>Homo sapiens</i> IGHG4*01 (CH1 (119-216), hinge S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide
tislélizumab	immunoglobuline G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-445) [VH humanisé (<i>Homo sapiens</i> IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) - <i>Homo sapiens</i> IGHG4*01 (CH1 (119-216), charnière S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":227-227")-bisdisulfure

tislelizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-445) [VH humanizado (*Homo sapiens* IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), bisagra S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (81.20%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG LVKPSSETLSL TCTVSGFSLT SYGVHWIROP PGKGLEWIGV 50
IYADGSTNYN PSLKSRVTIS KDTSKNQVSL KLSVTAADT AVYYCARAYG 100
NYWYIDVWGG GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPFPTVTSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTF SSSLGTHYTF 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP PVAGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVAVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTIVVHGD WLNGKEYKCK VSNKGLEFSI EKTISKAKGQ PREPQVYTL 350
PSQEEMTKNQ VSLTCLVKGK YPSDIAVEWE SNGQPENNYK TTPPVLCSDG 400
SFFLYSKLTV DKSRWQEGNV FSCSMHEAL HNHYTQKSL SLSLKG 445

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSESVS NDVAWYQQK QGPPKLLINY 50
AFHRFTGVPD RFSGSGYGT DFTLTISLQA EDVAVYYCHQ AYSSPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNEY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYERHK VYACEVTHQG 200
LSSPVTKSFN RGECC 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 145-201 259-319 365-423
22"-95" 145"-201" 259"-319" 365"-423"

Intra-L (C23-C104) 23"-88" 134"-194"
23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 132-214" 132"-214"

Inter-H-H (h 8, h 11) 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4;

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

tralesinidasum alfa #
tralesinidase alfa

human α -N-acetylglucosaminidase fused to truncated human insulin-like growth factor II (IGF2) via a peptide linker, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

human α -N-acetylglucosaminidase (NAG, EC=3.2.1.50) (1-720) fusion protein with glycyl-L-alanyl-L-prolyl-triglycyl-L-seryl-bis(L-prolyl-L-alanyl-L-prolyl-L-alanyl-L-prolyl-L-threonyl)-bis(L-prolyl-L-alanyl)-triglycyl-L-prolyl-L-seryl-glycyl-L-alanyl-L-prolyl-[37-L-alanine(R³⁷>A₍₇₈₁₎)]human insulin-like growth factor II (somatomedin-A, T3M-11-derived growth factor, IGF-II) (8-67)-peptide (752-811), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

tralésinidase alfa

alpha-N-acétylglucosaminidase humaine fusionnée au facteur II de croissance humain analogue à l'insuline (IGF2) tronqué, via un peptide de liaison, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

alpha-N-acétylglucosaminidase humaine (NAG, EC=3.2.1.50) (1-720) protéine de fusion avec glycyL-L-alanyl-L-prolyl(triglycyl-L-séryl-bis(L-prolyl-L-alanyl-L-prolyl-L-alanyl-L-prolyl-L-thréonyl)-bis(L-prolyl-L-alanyl)-triglycyl-L-prolyl-L-sérylglycyl-L-alanyl-L-prolyl-[37-L-alanine(R³⁷>A₍₇₈₁₎)]facteur II de croissance analogue à l'insuline humain (somatomédine-A, T3M-11-facteur de croissance dérivé, IGF-II) (8-67)-peptide (752-811), produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

tralesinidasa alfa

alfa-N-acetilglucosaminidasa humana fusionada con el factor II de crecimiento humano análogo a la insulina (IGF2) truncada, vía un péptido de unión, producida en las células ováricas de hamster chino (CHO), glicofoma alfa;

alfa-N-acetilglucosaminidasa humana (NAG, EC=3.2.1.50) (1-720) proteína de fusión con glicil-L-alanil-L-prolil(triglicil-L-seril-bis(L-prolil-L-alanil-L-prolil-L-alanil-L-prolil-L-treonil-bis(L-prolil-L-alanil)-triglicil-L-prolil-L-serilglicil-L-alanil-L-prolil-[37-L-alanina(R³⁷>A₍₇₈₁₎)]factor II de crecimiento análogo a la insulina humano (somatomedina-A, T3M-11-factor de crecimiento derivado, IGF-II) (8-67)-péptido (752-811), producido en las células ováricas de hamster chino (CHO), glicofoma alfa

Sequence / Séquence / Secuencia

```
DEAREAAAVR ALVARLLGPG PAADPSVSVE RALAAKPGLE TYSLGGGGAA 50
RVRVRGSTGV AAAAGLHRYL RDFCGCHVAV SGSQRLRP RP LPAVPGELTE 100
ATPNRYRYQQ NVCTQSYSEFV WDWARWERE IDWMLNGIN LALAWSGQEA 150
IWQRVYLALG LTQAEINEFF TGPAFLAWGR MGNLHTWDGP LPPSWHIKQL 200
YLQHRVLDQM RSFGMTFVLP AFAGHVPEAV TRVFPQNVNT KMGSWGHEFC 250
SYSCSFLLAP EDPIFPPIGS LFLRELIKEF GTDHIYGADT FNEMQPPSSE 300
PSYLAATAA VYEAMTAVDT EAVWLLQGWL FQHQPQFWGP AQIRAVLGAV 350
PRGELLVLDL PAESQPVYTR TASFGGQPF I WCMLHNFPGN HGLFGALEAV 400
NGGPEAARLF PNSTMVGTGM APEGISQNEV VYSLMAGLGN RKDPVPDLAA 450
WVTSFAARRY GVSHPDAGAA WRLLRSVYN CSGEACRGNH RSPVRRPSSL 500
QMNTSIWYNR SDVFPAWRL L TSAPSLATS PAFRYDLDDL TRQAVQELVS 550
LYYEARSAY LSKELASLLR AGGVLAYELL PALDEVLASD SRFLGSLNLE 600
QARRAAVSEA EADFEQNSR YQLTLWGPEG NILDYANKQI AGLVANYYTP 650
RWRLFLEALV DSVAQGIPIFQ QHQFDKNVFC LEQAFVLSKC RYPSQPRGDT 700
VDLAKKIFLK YYPWVAGSW GAPGGGSPAP APTPAPAPTP APAGGGPSGA 750
PLCGGELVDT LQFVCGDRGF YFSRPASRVS ARSRGIVEEC CFRSCDLALL 800
ETTCATPAKS E 811
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
74-76 250-254 481-486 753-791 765-804 790-795

Glycosylation sites(N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-238 Asn-249 Asn-412 Asn-480 Asn-490 Asn-503 Asn-509

Glycosylation sites(O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
Ser-727 Thr-733 Thr-739 Ser-748

trilaciclibum

trilaciclib


2'-[[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one

trilaciclib

2'-[[5-(4-méthylpipérazin-1-yl)pyridin-2-yl]amino]-7',8'-dihydro-6'*H*-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-*d*]pyrimidin]-6'-one

trilaciclib

2'-[[5-(4-méthylpipérazin-1-il)pyridin-2-il]amino]-7',8'-dihydro-6'*H*-spiro[cyclohexano-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-*d*]pyrimidin]-6'-ona

C₂₄H₃₀N₈O**vactosertibum**

vactosertib


2-fluoro-*N*-{[4-(6-méthylpyridin-2-yl)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)-1*H*-imidazol-2-yl]méthyl}aniline

vactosertib

2-fluoro-*N*-{[4-(6-méthylpyridin-2-yl)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)-1*H*-imidazol-2-yl]méthyl}aniline

vactosertib

2-fluoro-*N*-{[4-(6-méthylpyridin-2-il)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-il)-1*H*-imidazol-2-il]méthyl}anilina

C₂₂H₁₈FN₇**vadacabtagenum leraleucelum #**



vadacabtagene leraleucel



human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the SJ25C1 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (SFG-1928z CAR). Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

vadacabtagène léraleucel

Lymphocytes T humains autologues en culture d'expansion et modifiés génétiquement pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélevé chez le patient et sont transduites avec un vecteur rétroviral non-répliquant codant pour le récepteur de

	l'antigène chimérique SJ25C1 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) CD28/CD3zêta (SFG-1928z CAR). Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.
vadacabtagén leraleucel	Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector retroviral no replicativo que codifica para el receptor de antígenos quimérico SJ25C1 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) CD28/CD3zeta (SFG-1928z CAR). Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.
valzifloceptum # valziflocept	human immunoglobulin gamma Fc region receptor II-b (FcγRII-b), extracellular N-terminal fragment, produced in <i>Escherichia coli</i> ; human low affinity immunoglobulin gamma Fc region receptor II-b (IgG Fc receptor II-b, CDw32, Fc-gamma RII-b, FcRII-b, antigen CD32)-(4-179) peptide (N-terminal extracellular portion), produced in <i>Escherichia coli</i>
valziflocept	récepteur II-b de la région Fc de l'immunoglobuline gamma humaine (FcγRII-b), fragment extracellulaire N-terminal, produit par <i>Escherichia coli</i> ; récepteur II-b de faible affinité pour la région Fc de l'immunoglobuline gamma humaine (IgG Fc récepteur II-b, CDw32, Fc-gamma RII-b, FcRII-b, antigène CD32)-(4-179) peptide (partie extracellulaire
valziflocept	receptor II-b de la región Fc de la inmunoglobulina gamma humana (FcγRII-b), fragmento extracelular N-terminal, producido por <i>Escherichia coli</i> ; receptor II-b de baja afinidad para la región Fc de la inmunoglobulina gamma humana (IgG Fc receptor II-b, CDw32, Fc-gamma RII-b, FcRII-b, antígeno CD32)-(4-179) péptido (parte extracelular N-terminal), producido por <i>Escherichia coli</i>
Sequence / Séquence / Secuencia APPKAVLKLE PQWINVLQED SVTLTCRGTH SPESDSIQWF HNGNLIPTHT 50 QPSYRFKANN NDSGEYTCQT GQTSLSDPVH LTVLSEWLVL QTPHLEFQEG 100 ETIVLRCHSW KDKPLVKVTF FQNGSKKFS RSDPNFISIPQ ANHSHSGDYH 150 CTGNIGYTLY SSKPVTITVQ APSSS 176	
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 26-68 107-151	
vatinoxanum vatinoxan	<i>N</i> -{2-[(2 <i>R</i> ,12 <i>bS</i>)-2'-oxo-1,3,4,6,7,12 <i>b</i> -hexahydrospiro[[1]benzofuro[2,3- <i>a</i>]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl}methanesulfonamide

vatinoxan	<i>N</i> -{2-[(2 <i>R</i> ,12 <i>bS</i>)-2'-oxo-1,3,4,6,7,12 <i>b</i> -hexahydrospiro[[1]benzofuro[2,3- <i>a</i>]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl}méthanesulfonamide
vatinoxán	<i>N</i> -{2-[(2 <i>R</i> ,12 <i>bS</i>)-2'-oxo-1,3,4,6,7,12 <i>b</i> -hexahidrospiro[[1]benzofuro[2,3- <i>a</i>]quinolizina-2,4'-imidazolidin]-3'-il]etil}metanosulfonamida
	$C_{20}H_{26}N_4O_4S$
	
vecabrutinibum	
vecabrutinib	(3 <i>R</i> ,3' <i>R</i> ,4' <i>S</i>)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide
vécabrutinib	(3 <i>R</i> ,3' <i>R</i> ,4' <i>S</i>)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[[3-chloro-5-(trifluorométhyl)phényl]amino]-2-oxo-[1,3'-bipipéridine]-4'-carboxamide
vecabrutinib	(3 <i>R</i> ,3' <i>R</i> ,4' <i>S</i>)-1'-(6-amino-5-fluoropirimidin-4-il)-3-[[3-cloro-5-(trifluorometil)fenil]amino]-2-oxo-[1,3'-bipiperidina]-4'-carboxamida
	$C_{22}H_{24}ClF_3N_7O_2$
	
veldoreotidum	
veldoreotide	<i>N</i> ^{4.1} , <i>C</i> ^{α.8} -anhydro[<i>N</i> -(2-amino-2-oxoethyl)-4-aminobutanoyl-4-aminobutanoyl-L-phenylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanine]
veldoréotide	<i>N</i> ^{4.1} , <i>C</i> ^{α.8} -anhydro[<i>N</i> -(2-amino-2-oxoéthyl)-4-aminobutanoyl-4-aminobutanoyl-L-phénylalaninyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-thréonil-L-phénylalanine]
veldoreotida	<i>N</i> ^{4.1} , <i>C</i> ^{α.8} -anhidro[<i>N</i> -(2-amino-2-oxoetil)-4-aminobutanoil-4-aminobutanoil-L-fenilalanil-L-triptofil-D-triptofil-L-lisil-L-treonil-L-fenilalanina]

**vorasidenibum**



vorasidenib

6-(6-chloropyridin-2-yl)-*N*²,*N*⁴-bis[(2*R*)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine

vorasidénib

6-(6-chloropyridin-2-yl)-*N*²,*N*⁴-bis[(2*R*)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine

vorasidenib

6-(6-cloropiridin-2-il)-*N*²,*N*⁴-bis[(2*R*)-1,1,1-trifluoropropan-2-il]-1,3,5-triazina-2,4-diamina**zanubrutinibum**



zanubrutinib

(7*S*)-2-(4-phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrimidine-3-carboxamide

zanubrutinib

(7*S*)-2-(4-phénoxyphényl)-7-[1-(prop-2-enoyl)pipéridin-4-yl]-4,5,6,7-tétrahydropyrazolo[1,5-*a*]pyrimidine-3-carboxamide

zanubrutinib

(7*S*)-2-(4-fenoxifenil)-7-[1-(prop-2-enoyl)piperidin-4-il]-4,5,6,7-tetrahidropirazolo[1,5-*a*]pirimidina-3-carboxamida**zenocutuzumabum #**

zenocutuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) and *Homo sapiens* ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, bispecific;

	gamma1 heavy chain anti-ERBB3 (1-453) [<i>Homo sapiens</i> VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; gamma1 heavy chain anti-ERBB2 (1-450) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (233-230":236-233")-bisdisulfide
zénocutuzumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> ERBB3 (récepteur à activité tyrosine kinase erbB-3, HER3) et <i>Homo sapiens</i> ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticorps monoclonal humanisé, bispécifique; chaîne lourde gamma1 anti-ERBB3 (1-453) [<i>Homo sapiens</i> VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 anti-ERBB2 (1-450) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (233-230":236-233")-bisdisulfure
zenocutuzumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> ERBB3 (receptor de la actividad tirosina kinasa erbB-3, HER3) y <i>Homo sapiens</i> ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticuerpo monoclonal humanizado, biespecífico; cadena pesada gamma1 anti-ERBB3 (1-453) [<i>Homo sapiens</i> VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 anti-ERBB2 (1-450) [VH humanizado (<i>Homo sapiens</i> IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (233-230":236-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-ERBB3)

QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYMHVVRQA PGQGLEWMGW 50
 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSLRLSDC TAVYYCARDH 10C
 GSRHFWSYWG FDYWGQGLTV TVSSASTKGF SVFPLAPSSK STSGGTAALG 15C
 CLVKDYFPEF VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVTVFSSSL 200
 GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPFCFAPE LGGPSVFLF 250
 PFKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAFIE KTISKAKGQF 350
 REPQVYTKPP SREEMTKNQV SLKCLVKGFY PSDIAVEWES NGQPENNYKT 40C
 TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 45C
 SPG 453

Heavy chain / Chaîne lourde / Cadena pesada (anti-ERBB2)

QVQLVQSGAE VKKPGASVKL SCKASGYTFT AYYINWVRQA PGQGLEWIGR 50
 IYPSGYTCSY AQKFQGRATL TADESTSTAY MELSSLRSED TAVYFCARFP 10C
 VYDSAWFAY WGQGLTVTVS SASTKGPSVF FLAPSSKSTS GGTAAALGCLV 15C
 KDYFPEFPTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
 TYICNVNHKF SNTKVDKRVK PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAIEKTI SKAKGQPREP 350
 QVYTDPPPRE EMTKNQVSLT CEVKGFPYPSD IAVEWESNGQ PENNYKTTTP 40C
 VLDSGDSFPL YSKLTVDKSR WQQGNVFSQS VMHEALNHYH TQKSLSLSPG 45C

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVTI ITCRASQSI SYLNWYQKPK GKAPKLLIYA 50
 ASSLSQGVPS RFGSGSGSDT FTLTISLQPE EDFATYYCQQ SYSTPPTFGQ 10C
 GTKVEIKRTV AAPSVEIFPP SDEQLKSGTA SVVCLLNRFY PREAKVQWVK 15C
 DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYERKH VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 151-207 268-328 374-432
 22"-96" 148"-204" 265"-325" 371"-429"

Intra-L (C23-C104) 23'-88' 134'-194'

23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 227-214' 224"-214"

Inter-H-H (h 11, h 14) 233-230" 236-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

304, 301"

Defucosylated ($\geq 90\%$) complex bi-antennary CHO-type glycans / glycanes de type CHObi-antennaires complexes défucosylés ($\geq 90\%$) / glicanes de tipo CHO biantenaricomplejos defucosilados ($\geq 90\%$)**zolbetuximabum #**

zolbetuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], chimeric monoclonal antibody;
 gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) - (IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227":230-230")-bisdisulfide

zolbétuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CLDN18 (claudine 18, claudine-18, SFTPJ, surfactant associé à la protéine J) isoforme 2, domaine extracellulaire 1 (EC1)], anticorps monoclonal chimérique;
 chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) - (IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (227-227":230-230")-bisdisulfure

zolbetuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CLDN18 (claudina 18, claudina-18, SFTPJ, surfactante asociado a la proteína J) isoforma 2, dominio extracelular 1 (EC1)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) -(IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQPGAE LVRPGASVKL SCKASGYTFT SYWINWVKQR PGQGLEWIGN 50
IYPSDSYTNV NQKFKDKATL TVDKSSSTAY MQLSSPTSED SAVYYCTRSW 100
RGNFSDYWGQ GTTLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTWSN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSTIAV EWESNGQPEN NYKTTTPPYLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPSS LTVTAGEKVT MSCKSSQSLN NSGNQKNYLT WYQKPGQPP 50
KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY 100
PFTFGSGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNFPYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"

Intra-L (C23-C104) 23'-94' 140'-200'
23'''-94''' 140'''-200'''

Inter-H-L (h 5-CL 126) 221-220' 221"-220"

Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaire complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

Electronic structure available on Mednet: <http://mednet.who.int/>

Structure électronique disponible sur Mednet: <http://mednet.who.int/>


Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

* <http://www.who.int/medicines/services/inn/publication/en/>

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 47
Dénominations communes internationales recommandées (DCI Rec.): Liste 47
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 47
(WHO Drug Information, Vol. 16, No 1, 2002)

- p. 84 **alicaforsenum**
alicaforsen *replace the chemical name and the molecular formula by the following ones*
alicaforsen *remplacer le nom chimique et la formule moléculaire brute par les suivants*
alicaforsén *sustitúyase el nombre químico y la fórmula molecular por los siguientes*
- all-P-(R)-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxyadenosine*
- tout-P-(R)-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxyadénosine*
- todo-P-(R)-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxiadenosina*



Recommended International Nonproprietary Names (Rec. INN): List 71
Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No 1, 2014)


p. 101 **patisiranum**

patisiran

patisiran

patisirán

replace the molecular formula by the following one
remplacer la formule moléculaire brute par la suivante
sustitúyase la fórmula molecular por la siguiente



Recommended International Nonproprietary Names (Rec. INN): List 75
Dénominations communes internationales recommandées (DCI Rec.): Liste 75
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 75
(WHO Drug Information, Vol. 30, No 1, 2016)


p. 105 **cenerimodum #**

cenerimod

cénérimod

cenerimod

replace the structure by the following one
remplacer la structure par la suivante
sustitúyase la estructura por la siguiente



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.